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Abstract 
 
Plasminogen activator inhibitor type-1 (PAI-1) is a member of the serine protease inhibitor 
(serpin) superfamily. Excessive levels of PAI-1 inhibit urokinase-type plasminogen activator 
(uPA) and tissue-type plasminogen activator (tPA), which regulates fibrinolysis as well as the 
development of different pathological diseases like obesity, metabolic syndrome, tumor invasion 
and metastasis, and coronary heart disease. Currently, there is no Food and Drug Administration 
approval for inactivating higher levels of PAI-1. Therefore, PAI-1 is considered an attractive 
drug target.  Due to PAI-1’s different structural conformations and multiple binding domains, 
development of PAI-1 inhibitors is a challenging situation. In this research study, we describe the 
synthesis and evaluation of novel low molecular weight amides containing various moieties, 
including para-chlorobenzyl, polyphenol, oxindole, or isatin-based units. By changing the 
architectural scheme of these compounds we hope to effectively change the potency of our 
inhibitors, and will be able to develop a structure-activity relationship that will allow us to design 
a more potent small molecule as a PAI-1 inhibitor. Therefore, the synthesis and structure-activity 
relationship of those novel small molecules are discussed in this paper.     
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Chapter I: Plasminogen Activator Inhibitor-1 (PAI-1) 
I-1: Serpin Superfamily  
The serine protease inhibitor (serpin) protein superfamily1 has been identified with over 
1500 members in different living sources such as animals, poxviruses, plants, bacteria, and 
archaea.2,3,4 The products of these serpin genes are well known for the inhibition of serine 
proteases, but not all of them perform inhibitory functions. The non-inhibitory serpins are 
involved in different mechanisms such as hormone transportation. Among the vast number of 
serpin members, 36 are identified as human coded functional proteins.5 Given below are a few 
different types of human serpins, including their functions and dysfunctions in the human system 
(Table 1).  
 
Table 1: Human serpins and their function / dysfunction.2,6,7  
 
Serpin Type Protease Target Disease Type Related to 
Abnormal Levels 
Antitrypsin (SERPINA1) Neutrophil elastase inhibition 
in extracellular matrices  
Low levels: emphysema 
Plasminogen activator 
inhibitor-1(PAI-1)(SERPIN1) 
tPA/uPA, thrombin, and 
plasmin inhibition in 
extracellular matrices  
Bleeding abnormality related 
diseases  
PAI-2 (SERPINB2) uPA inhibition in intracellular 
matrices 
Cancer 
PAI-3 (SERPINA5) Active protein C inhibition in 
extracellular matrices  
Deep-vein thrombosis, 
pulmonary embolism 
 
Antithrombin (SERPINC1) Thrombin and factor Xa 
inhibition in extracellular 
matrices  
Low levels: thrombosis  
Protein Z-dependent 
proteinase inhibitor 
(SERPINA10) 
Activated factor Z and XI 
inhibition in extracellular 
matrices 
Low levels: Venous 
thromboembolic disease  
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In early work concerning the PAI proteins, it was difficult and confusing to distinguish 
between the three plasminogen activator inhibitors, PAI-1, PAI-2, and PAI-3. This was mainly 
due to the unavailability of proper assays.8 Studies were later conducted on PAI-1 using specific 
assays, first identified7 and solidified in 1984,9 after which PAI-1 became of interest for further 
study. Among these plasminogen activator inhibitors, PAI-2 plays an important role during 
pregnancy. Under normal conditions, the presence of PAI-2 in plasma is minimal; during 
pregnancy, PAI-2 is secreted at higher levels and specifically inhibits urokinase-type 
plasminogen activator (uPA) and 2-chain tissue-type plasminogen activator (tPA).8,10 In addition, 
excess levels of PAI-2 are correlated with breast cancer.7 PAI-3, also called protein C inhibitor, 
is secreted in several tissues (liver, kidneys, prostate, testes and pancreas), and it plays a major 
role in fertilization and acts as a protease inhibitor in the male reproductive organs. In addition, 
PAI-3 forms a complex with uPA to play a pivotal role in anticoagulation in the protein C 
pathway in human plasma.6,11 Due to our key interest in PAI-1 inhibition, this introduction 
discusses background studies of PAI-1 structure, its role in blood coagulation and in fibrinolysis, 
early PAI-1 inhibitors and their problems, and current research regarding PAI-1 inhibitors.  
 
I-2: Plasminogen Activator Inhibitor Type 1 (PAI-1) – Background and Roles in Diseases.  
Plasminogen activator inhibitor type-1 (PAI-1) is the most important and rapid inhibitor 
of uPA and tPA.12 According to the studies by Dieval and coworkers, deficiency of PAI-1 leads 
to a delay in bleeding disorder (hemorrhage / hyperfibrinolysis)13 due to the high activity of tPA 
and insignificant amount of detectable tPA/PAI-1 complexes.14 Low levels of active PAI-1 are 
correlated with high activity of tPA/uPA because the presence of PAI-1 reduces the amount of 
active tPA/uPA by producing covalently bonded tPA/PAI-1 or uPA/PAI-1 complexes. At normal 
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physiological levels, PAI-1 is involved in multiple tasks, including fibrinolysis (the normal 
breakdown of blood clots), which is required for a well-functioning mammalian system. PAI-1’s 
main function is to regulate fibrinolysis by inhibiting the conversion of inactive plasminogen into 
an active plasmin by tPA or uPA (Figure 1).  Plasmin then reacts with fibrin clots and converts 
into its degradation products. In contrast, elevated levels of PAI-1 inhibit uPA/tPA, which leads 
to hypofibrinolysis, an abnormal increase in the level of blood clots.15-17 Studies have shown that 
a number of blood related diseases are associated with these excessive levels of PAI-1.18,19   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: PAI-1’s role in fibrinolysis. Green arrows denote stimulation and red arrows denote 
inhibition.   
 
At the normal biological levels in a healthy person, PAI-1 plays a pivotal role in 
fibrinolysis, as well as in angiogenesis,20 cell migration,21 and wound healing.22 It is expressed in 
vascular muscle cells, hepatocytes, adipose tissues, and platelets at low concentrations.23,24 In 
PAI-1 
uPA/tPA 
Plasminogen 
Activation 
Plasminogen Plasmin 
Fibrin 
Degradation 
products 
PAI-1 uPA/tPA 
 
Fibrin clots 
 
Fibrin 
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addition, due to different molecular mechanisms, excretion and storage of PAI-1 is varied by 
each cell type.25,26 However, in pathological conditions, PAI-1 expresses in higher concentrations 
and is associated with an extensive number of pathological diseases such as obesity, metabolic 
syndrome, tumor invasion and metastasis, and coronary heart disease,23,24 but the mechanism of 
PAI-1 involvement in the development of these diseases is not clear.27  
   PAI-1 is a 50 kDa glycoprotein28 made up of an approximately 400 amino acids.3,29 
PAI-1 consists of three β-sheets (A, B, and C),2,30 nine α-helixes (termed as A-I),30 and a flexible 
reactive center loop (RCL) (Figure 2-a). The RCL comprises a 20 to 30 amino acid sequence 
(represented as P16 – P’10)27,31 that specifically targets certain proteases by serving as “bait”. That 
part of the RCL contains the scissile bond at the location of P1-P1’18,32 and is exposed to solvent. 
The target proteases uPA/tPA bind to the RCL in the active form of PAI-1 and lead to the 
formation of a non-covalent Michaelis complex33,34 that acts as an intermediate between active 
PAI-1 and cleaved PAI-1. Once cleaved via proteolysis, the amino-terminal end of the RCL 
travels away from β-sheets B and C and flips nearly 180º to insert into β-sheet A. If the protease 
is able to complete its catalytic cycle and break its covalent bond to the RCL before the RCL 
inserts into β-sheet A, the cleaved form of PAI-1 and the regenerated active protease are formed 
(Figure 2-d). If the protease is not able to complete its catalytic cycle and break its covalent 
bond to the RCL before the RCL inserts into β-sheet A, the inactive protease/PAI-1 covalent 
complex is formed34 (Figure 2-c). At this stage, the serpin is kinetically stable and increases its 
thermal stability. Therefore, this conformational change is termed a “stressed” to “released” 
transition.12,18,29 
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Figure 2: The PAI-1 structure and its mechanism: (a) The structure of the active PAI-1 RCL is 
in magenta, (b) Initial Michaelis complex; protease non-covalently bound to RCL of PAI-1. (c) 
The final covalent serpin-enzyme complex. (d) Inactive PAI-1 in its cleaved form and the 
detached active protease.  
 
In addition, the spontaneous conversion of PAI-1 from the active form to the inactive 
latent form (Figure 3b) has a half-life of 1-2 hours at 37 oC,25,34,35 which prevents formation of a 
Michaelis complex with its target proteases. During this transition from the active to latent form, 
the RCL is inserted into β sheet A while releasing the first strand of β sheet C.32 Additionally, 
PAI-1 activity may vary according to its environmental conditions. For example, vitronectin is a 
70 kDa glycoprotein that binds with PAI-1 and is normally present in plasma and the 
extracellular matrix.27,36 (Figure 3c). When PAI-1 is bound to vitronectin, the active form of 
PAI-1 is stabilized by prolonging its half-life from 2-145 hours,36 and allows greater interaction 
with its target proteases.  Because of PAI-1’s several different conformational structures (active, 
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latent, covalent complex, cleaved, and vitronectin-bound) the development of PAI-1 inhibitors is 
challenging.  
 
 
 
Figure 3: Different conversions of active serpin. (a) Structure of active PAI-1, (b) 
Spontaneously converted inactive latent form. (c) Inactive cleaved form (d) Vitronectin-bound 
PAI-1. 
 
I-3: PAI-1 as a Drug Target 
 
As a pharmacological target, designing an active PAI-1 inhibitor is an attractive goal. 
One method is to prevent the secretion of excess levels of PAI-1 from particular cells. However, 
PAI-1 production is varied according to different cell types; hence, it is difficult to develop 
PAI-1 inhibitors particularly for each cell type. Despite this challenge, some compounds have 
been reported for the inhibition of PAI-1 production in the endothelial cells.26 For example, 
gemfibrozil is able to reduce the PAI-1 expression from endothelial cells.37 Conversely, a more 
straightforward approach is to inhibit excessive levels of PAI-1 directly because drugs can easily 
access the blood stream and can immediately display antithrombotic activity.  
(a) Active        (b) Latent                     (c) Cleaved      (d) Vitronectin bound 
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The biological activity of a synthesized inhibitor is characterized by its half maximal 
inhibitor concentration (IC50) value, which is the concentration of an inhibitor required to reduce 
its target’s activity to 50%. In Figure 4, the graph represents the IC50 value of a synthesized 
compound in the lab. This graph was created by plotting percent serpin activity (Y axis) versus 
the concentration of a particular inhibitor (X axis), and the IC50 is determined by reading the 
inhibitor concentration reading at 50% serpin activity. The potency of an inhibitor increases as 
the IC50 value decreases. In other words, if the IC50 values are from mM to µM to nM range, 
inhibitors express minimal to moderate to excellent activity, respectively.  
 
Figure 4: Plot of IC50 value for CDE-089 
According to the theory of direct inhibition of PAI-1 in plasma, since the 1990s, a 
number of researchers have synthesized molecules as PAI-1 inhibitors. However, none of these 
compounds were able to be used as a clinical drug molecule because those compounds have 
complications and some major drawbacks in vitro as well as in vivo. Dried roots of Salvia 
miltiorrhiza (danshen), a traditional Chinese medicine, have been used to treat stroke that is 
mainly related to clot formation or thrombosis. Californian Indians had used Salvia columbriae 
for the similar treatment. Tanshinones and salvianolic acids are the major active ingredients in 
both natural products. In further studies, seven natural compounds were isolated from Salvia 
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miltiorrhiza extract and were analyzed against PAI-1 inhibitory activity. Those seven natural 
products are tanshinone I, tanshinone IIA, sodium tanshinone IIA sulfonate, cryptotanshinone, 
sodium danshensu, protocatechuic aldehyde, and β-sitosterol.  Among those, sodium tanshinone 
IIA sulfonate (I-1) and cryptotanshinone (I-2) were identified with PAI-1 inhibitory activity in 
dose dependent manner, and it was confirmed that tanshinones are able to decrease the formation 
of the PAI-1/uPA complex and prevent fibrin clot formation.38  
  
In addition to natural products, several research studies have reported monoclonal 
antibodies, peptides, and small molecules as effective PAI-1 inhibitors.39 Monoclonal antibodies 
(MA) have become a topic of interest since the late 1980s. MAs are low molecular weight 
proteins with a molecular weight of approximately 150 kDa, which are designed to specifically 
bind to only one certain molecule; therefore, they are of potential therapeutic use as PAI-1 
inhibitors40 or as compounds that promote conversion to the latent form.31 In 1998 Ngo and 
Declerck developed MA-124K1, which showed an approximately 60% PAI-1 neutralizing 
property in vivo using pre-treated endotoxin in rats.40 MA-33H1F7, a monoclonal antibody 
studied in 1998, showed antithrombotic activity in humans and rat models by orienting PAI-1 
into a non-inhibitory substrate;41 however, MA-33H1F7 shows lower activity towards 
glycosylated PAI-1.42 Most of the other available monoclonal antibodies were characterized 
9 
 
against recombinant non-glycosylated PAI-1 in animal models. For example, MA33B8 is able to 
prevent the recognition of target proteases of the PAI-1 RCL and prevent RCL cleavage by 
converting PAI-1 into the inactive latent form.31 MA-8H9D4 and MA-55F4 were able to prevent 
formation of initial Michaelis complex with tPA/uPA by binding these monoclonal antibodies 
directly with RCL.31 Even though these monoclonal antibodies are exciting therapeutic methods 
for the inhibition of excess PAI-1 levels, use of monoclonal antibodies requires the improvement 
of specific drug delivery methods because antibody-based drugs can be rapidly destabilized and 
show decreased efficacy by changes in its environment, such as in pH. 
A number of studies have investigated the use of peptides as PAI-1 inhibitors. In 1995, 
Eitzman and coworkers used a SDS-PAGE analysis to show a 14-amino acid peptide (P1-P14) 
that could inhibit formation of the PAI-1/tPA complex, leading to the acceleration of fibrinolysis 
by rapid inhibition of PAI-1 in vitro.28 In another study, paionin-4, identified from a phage-
displayed peptide library, binds to PAI-1 in the same region that binds with MA33B8, and 
paionin-4 increases the rate of conversion from active to latent form. It is hypothesized that 
paionin-4 accelerates the conversion rate by stabilizing the transition state  leading to RCL 
insertion.30 However, similar to monoclonal antibodies, peptides are also not ideal drug 
candidates due to the lack of metabolic stability and efficacy in vivo.  
Therefore, the design of orally effective small molecules was becoming of greater 
importance to overcome complications that were associated with monoclonal antibodies and 
10 
 
peptides.  During the mid-1990s, the first reported small-molecule PAI-1 inhibitors were 
diketopiperazine derivatives by Xenova Limited named XR330 (I-3) and XR334 (I-4) that were 
isolated from the mycelium of an unidentified species of Streptomyces. XR330 and XR334 were 
able to inhibit PAI-1/tPA interaction in vitro with an IC50 value of 51 µM, and did not affect tPA 
activity. In addition, those compounds were found to have limited solubility. Ex vivo studies 
showed XR334 could enhance fibrinolysis and prolong the thrombus formation time in rats.43 By 
modifying these lead molecules, XR5118 (I-5) was selected for further studies in vivo to seek the 
improvement of potency and solubility.44 In vitro assay results (IC50 = 3.5 µM) and in a rat 
thrombosis model showed that inhibition of PAI-1 by XR5118 was selective over other serpins 
and enhanced fibrinolysis while increasing tPA activity in plasma, which indicated a possible 
treatment for thrombotic disease.44 However, these diketopiperazine derivatives still experienced 
poor physiochemical properties.18,45  
 
Among the small molecule inhibitors, the most studied PAI-1 inhibitor to date is PAI-039 
(also called tiplaxtinin) (I-6), which has an IC50 value of 2.7µM versus PAI-1. Although it has 
activity against PAI-1 in animal models, it was not clinically approved due to low affinity to 
PAI-1, and the inability to inactivate PAI-1 in the presence of vitronectin.23,46 Research has been 
11 
 
done to investigate PAI-039’s mechanism of inhibition using SPR (surface plasmon resonance) 
analysis, and data shows that PAI-039 binds reversibly only to free PAI-1, and displays its anti-
proteolytic activity against uPA/tPA with an IC50 value of 9-12 µM. Also, there is no binding 
observed with PAI-1 that is already bound to vitronectin or that exists in the latent 
conformation.23  
 
Wyeth also developed WAY-140312 (I-7), which in the presence of tPA or uPA inhibits 
PAI-1 with an IC50 value of 11.7 µM. When tested in animal models of vascular injury, a 10 mg-
kg-1 oral dose of WAY-140312 was required to reduce thrombotic diseases and displayed only a 
29% bioavailability with a very low half-life (1 hour).45 In 2008, Rupin and co-workers had 
tested S35225 (I-8), a benzothiophene derivative, in in vitro and in vivo studies side-by-side with 
tiplaxtinin and WAY-140312. These studies showed that when they were intravenously 
administered, only S35225 inhibited PAI-1 activity in a dose-dependent fashion after 15 minutes 
in rat models, which indicated that this benzothiophene derivative is a direct PAI-1 inhibitor and 
in inhibits the development of clots. Even though S35225 is able to inhibit PAI-1 immediately 
after injection in the presence of vitronectin, S35225 is not useful for a long-term treatment due 
compared to tiplaxtinin and WAY-140312. Therefore, to increase the efficacy of direct PAI-1 
inhibition in blood, S35225 led to further improvement.47  
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ZK4044 (I-9), a menthol-based compound, was identified using high throughput library 
screen, and displayed an IC50 of 0.644 µM against PAI-1. ZK4044 selectively binds to PAI-1 
over other serpins, such as antithrombin III, α-2 antitrypsin, and α-2 antiplasmin. In addition, this 
compound directly inhibits PAI-1 by preventing interaction with tPA/uPA. Furthermore, ZK4044 
is able to prevent PAI-1’s conversion from active to latent form.26 However, it requires further 
optimization for improved water solubility because of its hydrophobic menthol based chemical 
structure.  
 
By utilizing the high throughput library screen, Jain et.al. identified an oxamic acid-based 
lead compound (I-10) with an IC50 value of 96 µM in vitro.
48 They were able to synthesize a 
series of structural analogs (I-11, I-12) by optimizing the aromatic substitution while retaining 
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the carboxylic acid functionality. Of the series of synthesized compounds, I-12 showed good 
inhibitory activity compared to the lead molecule. However, due to the poor oral bioavailability 
of the derivatives, they displayed poor pharmacokinetics, and it was not further evaluated.49  
Another study reported piperazine derivative I-13, which was also identified from a high 
throughput library screen, with an IC50 value of 1.8 µM against PAI-1. Due to the phosphonic 
acid moiety, this compound is associated with poor oral bioavailability.39 Therefore Ye et.al. 
studied the structure-activity relationship using different analogs of I-13 by modifying the 
structure in three different segments. Replacement of the aminomethyl phosphonic acid with a 
substituted benzoic acid moiety (I-14) showed improved potency against PAI-1, with an IC50 of 
0.5 µM. Given I-14’s selectivity for PAI-1 over other serpins, it was then tested in rats to 
determine its pharmacokinetic properties. The results showed that oral bioavailability improved 
to 43% with a moderate clearance rate of 10.4 ml/min/kg compared to the menthol based 
compound I-9; additionally, the inhibitor showed an extended half-life of 2.8 h.39  
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Pandiya and coworkers also synthesized structural analogs (I-15 and I-16) that are 
hybridized versions of the benzoic acid moiety of I-14 with tiplaxtinin (I-6) and piperazine 
derivative I-13. These hybrid versions showed good PAI-1 inhibitory activity in vitro but failed 
or showed moderate antithrombotic activity in rat models.49 Therefore, to improve the 
pharmacodynamics and pharmacokinetic properties, further efforts are in progress.  
With the intention of developing more potent novel molecules with relatively high 
affinity for PAI-1 and the ability to inhibit vitronectin-bound PAI-1, our research group started a 
collaboration with Professor Daniel Lawrence’s lab at the University of Michigan Medical 
School in 2007. Using a high throughput screen of the MicroSource SPECTRUM compound 
library, the Lawrence group was able to identify 19 structurally varied compounds that showed 
activity against PAI-1, three of which contained galloyl moieties (3,4,5-trihydroxybenzoates).46 
15 
 
These compounds allowed our group to develop a new class of novel polyphenolic PAI-1 
inhibitors (Figure 5). These compounds showed better PAI-1 inhibitory activity than tiplaxtinin, 
were able to block the formation of the initial Michaelis-like complex between PAI-1 and 
tPA/uPA, and also were shown to inhibit vitronectin-bound PAI-1. In addition, these compounds 
can reversibly bind PAI-1 with high affinity, which means the IC50 is not time dependent. 
However, none of the digallate analogs (CDE-008 I-17, CDE-031 I-18, CDE-034 I-19, CDE-056 
I-21) (Figure 5) had an acceptable activity against PAI-1 in ex vivo experiments containing 
plasma proteins. On the other hand, compounds with more galloyl groups, such as CDE-066 (I-
20) and CDE-082 (I-22), displayed better activity than the above digallate compounds against 
PAI-1 in plasma.46 Generally, the trend was that the greater the number of galloyl groups, the 
better the inhibitory activity against PAI-1. However, CDE-066 (I-20) has a molecular weight 
nearly 2000 daltons and as such it cannot be considered as an ideal drug candidate. Also, in these 
polyphenolic compounds, the galloyl groups are attached via ester linkages, which are unstable 
in acidic media. If these are used as drug molecules, when orally administered, the ester can be 
easily hydrolyzed into the corresponding carboxylic acids and alcohols.  
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Figure 5: Second generation galloyl compounds46  
Our research group then worked on designing a next generation of analogs of different 
polyphenolic compounds, which typically contain 3,4-dihydroxybenzene moieties linked with 
sulfonyl groups instead of ester linkages (Figure 6). Those bis-arylsulfonamides and 
arylsulfonimides are intended to be more biostable than the previous generation of  polyphenolic 
compounds, as the sulfonamide linking unit is widely used in FDA-approved drugs. Different 
symmetric and non-symmetric molecules were designed by increasing the tether length between 
sulfonamide groups or by substituting an alkyl group for an acidic proton on nitrogen, and the 
resulting inhibitory activity against PAI-1 was determined. Many of these compounds showed 
better activity than tiplaxtinin, and showed high specificity for PAI-1 over anti-thrombin III 
(ATIII), a structurally related mammalian serpin.50 However, even though the bis-
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arylsulfonamides and arylsulfonimides selectively inhibit PAI-1, these compounds also lose their 
activity in plasma. 
 
Figure 6: Third generation bis-arylsulfonamides and arylsulfonamides.  
 
These studies showed that none of the compound were able to inhibit PAI-1 while 
providing all the requirements to be a potent PAI-1 inhibitor in vitro and in vivo. Hence, this 
provides the foundation for the design of novel group of inhibitors with a low IC50 value that are 
able to inhibit the activity of free PAI-1 as well as vitronectin-bound PAI-1.12 Therefore, the 
Lawrence lab carried out a second library screen from University of Michigan Center for 
Chemical Genomics (CCG) library and identified a low molecular weight compound with a 
relatively low IC50 value versus PAI-1 in the presence of plasma (Figure 7). This compound 
inspired us to design next generation analogs of novel low molecular weight amides containing 
various replacement groups and moieties. From this collection of structurally diverse inhibitors, 
we set out to develop a structure-activity relationship for this class of compound that will allow 
us to design a more potent small molecule as a PAI-1 inhibitor.    
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Figure 7: Second library screened leading molecule (I-27).  
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Chapter II: Next Generation Novel Small Molecules as PAI-1 Inhibitors 
 
Our previous series of polyphenolic PAI-1 inhibitors, which contain galloyl moieties or 
3,4-dihydroxybenzene sulfonamide groups, were able to provide good inhibitory activity versus 
PAI-1 in a standard buffer solution, but activity was destroyed when plasma was added. This is 
because of the poor availability of our inhibitors due to the preferential binding to other proteins 
present in plasma. Because of this, our focus is to improve the potencies of our inhibitors with 
PAI-1 in a plasma-containing assay. Therefore, our collaborators carried out a second library 
screen and identified a hydrazide (I-27) with an IC50 value of 36 µM in a plasma-containing 
assay.  
 
 
Figure 8: Structural modifications of lead molecule 
This compound led us to synthesize structural analogs by modifying the substituents on 
the aromatic ring and/or varying the nature of the hydrazide group. We developed different 
esters, carboxylic acids, and substituted hydrazides, with various substituents on the aromatic 
ring. Also, to probe PAI-1 inhibitory activities we modified the hydrazide group by adding 
substituents or by replacement with a polyphenolic moiety (Figure 8). By analysis of the effects 
of these key modifications on IC50 values, we were able to start to develop a structure-activity 
relationship for this class of molecules versus PAI-1.  
I-27 
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As shown in Scheme 1, I chose differently substituted benzyl amines and treated them 
with ethyloxalyl chloride in the presence of pyridine to obtain the respective ester analogs. Our 
desired hydrazides were obtained by treating this ester compound with a 50% aqueous hydrazine 
solution. Also, the same ester compound was used to do the hydrolysis to attain the respective 
carboxylic acid, which was then coupled with differently substituted hydrazides to obtain the 
final diamides.  
 
Scheme 1: General synthetic method for hydrazide analogs of lead molecule 
 
II-1: Effect of changing aromatic ring substituents on ester, carboxylic acid, and hydrazide 
analogs. 
Early in my research, my main focus was to synthesize different hydrazide compounds 
with variously substituted aromatic rings. The synthetic pathway (Scheme 1) proceeded through 
an ester intermediate. Some of the ester intermediates were also submitted for biological testing 
in order to compare the IC50 values of the esters with the corresponding hydrazides. In the ester 
compounds, mono-para-substituted aromatic rings with different halides or a nitrile showed 
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lower PAI-1 inhibitory activity compared to same substitution pattern in hydrazide compounds 
(Table 2). For example, considering ester compounds in a plasma-containing assay, the para-
chloro substitution (CDE-444) exhibited an IC50 of 1799 µM. Replacement with bromine (CDE-
259) yielded three-fold better inhibitory activity, whereas replacement with fluorine (CDE-247) 
lost activity in standard buffer and was therefore not tested in a plasma-based assay.  However, if 
the benzene ring contains a substituent (CF3 group) at the meta position in addition to the para-
chloro substituent, the ester compound (CDE-256) and hydrazide compounds (CDE-251, CDE-
261 and CDE-297) showed good inhibitory activity against PAI-1. Additionally, we tested two 
different carboxylic acids by altering the substituents at para position while keeping a CF3 group 
at the meta position, but none of those compounds showed good inhibitory activity (Table 3). As 
for the hydrazides (Table 4), benzene moieties with para and meta substituted compounds show 
comparatively two- to three-fold higher IC50 values to our lead molecule and consistent values in 
each of the three different assays. These results indicated that EWGs at meta and para positions 
are beneficial for PAI-1 inhibitory activity. Therefore, we selected the para-chloro-meta 
trifluorobenzene moiety as the standard substitution pattern for synthesizing further small 
molecules. 
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Table 2: Comparison of IC50 (µM) values of ester analogs. 
 
Code R3 R4 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-444 H Cl 1799 2847 1062 
CDE-247a H F NT >3000 NT 
CDE-259a H Br 526 2998 694 
CDE-319 H CN NT >1000 NT 
CDE-256b CF3 Cl 214 1353 235 
aCompound synthesized by Naga Guntaka. bCompound synthesized by Greg Abernathy. NT: not 
tested. 
 
Table 3: Comparison of IC50 (µM) values of carboxylic acid analogs. 
Code R4 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH7.4 
1.5% BSA 
CDE-311 H NT >3000 NT 
CDE-309a Cl >3000 1200 >3000 
 
aCompound synthesized by Dan Van Strien. NT: not tested 
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Table 4: Comparison of IC50 (µM) values of hydrazide analogs.  
Code R3 R4 R5 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
Lead H Cl H 36 117 54 
CDE-248a H F H 478 1313 648 
CDE-260 H Br H 52.5 166 50 
CDE-251b CF3 Cl H 108 76 123 
CDE-261b CF3 F H 69 76 102 
CDE-297 CF3 H H 87 128 111 
CDE-304 F F F 74 162 90 
CDE-336 H CN H 851 5469 892 
 
aCompound synthesized by Naga Guntaka. bCompound synthesized by Greg Abernathy. NT: not 
tested. 
Some of the compounds were not tested in assays containing plasma or 1.5% BSA 
because those showed minimal potencies in simple buffer. As seen in Tables 2-4, even if we 
change the substitution pattern on the aromatic ring, the hydrazide analogs possess better 
inhibitory activity compared to ester and carboxylic acid analogs.  
II-2: Effect of changing hydrazide substituents  
Then we determined the IC50 values by designing compounds that replaced or substituted 
the hydrazide group with different moieties while keeping the left-hand side aromatic moiety 
constant. Substitution onto the terminal nitrogen atom of the hydrazide with different 
substituents (Table 5) did not show good inhibitory activity in simple buffer, except for CDE-
334. In CDE-334, substituting with benzene sulfonyl group resulted in good inhibitory activity in 
simple buffer but activity was destroyed when plasma or 1.5% BSA was added to it. In contrast, 
if the entire terminal NH2 group was replaced with different substituents (Table 6), compounds 
containing a hydroxamate (CDE-280, CDE-320) showed IC50 values between 150-700 µM 
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range. However, if the entire hydrazide unit (ie. the carbonyl and both nitrogens) was removed, 
as in Table 7, and replaced with a group that does not contain a catechol unit, all the compounds 
lost any significant activity in a simple buffer solution. Due to this reason, those were not tested 
in the other assay systems.  
Table 5: Substituent on hydrazide group - substitute one hydrogen.  
Code R4 R’ 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-310 H 
 
NT >1000 NT 
CDE-298a Cl 
 
NT >1000 NT 
CDE-333 Cl 
 
NT >100 NT 
CDE-334 Cl 
 
>300 189 >300 
aCompound synthesized by Greg Abernathy. NT: not tested. 
 
Table 6: Substituents on hydrazide group - substitute NH2 group.  
Code R4 R’ 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-280a Cl 
 
168 203 159 
CDE-320 Cl 
 
693 329 513 
CDE-335 Cl 
 
NT >100 NT 
aCompounds synthesized by Greg Abernathy. NT: not tested. 
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Table 7: Substituents on hydrazide group - replace hydrazide and one carbonyl, with different 
substituents.  
Code R 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-349a 
 
NT >300 NT 
CDE-354 
 
NT >300 NT 
CDE-355 
 
NT >300 NT 
aCompound synthesized by Naga Guntaka. NT: not tested. 
 
 
II-3 Effect of increasing the chain length between carbonyl group and catechol unit 
We also synthesized hybrids of the two major classes of PAI-1 inhibitors that our lab has 
studied by replacing the hydrazide unit in our above scaffold with a catechol group. These 
hybrids were synthesized according to the procedure shown in Scheme 2; potencies against PAI-
1 are shown in Table 8.  
 
Scheme 2: Synthesis of peptide coupling products 
Differently substituted benzylamines were treated with 3,4-dihydroxybenzoic acid or 
(3,4-dihydroxyphenyl)acetic acid or 3-(3,4-dihydroxyphenyl)propanoic acid under standard 
peptide-coupling conditions to yield the target amides with a varying tether length between the 
amide group and the catechol unit. 
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Table 8: Change of tether length comparison (a) IC50 values when n = 0, 1, 2 (b) comparison 
table. 
 
Code n R2 R3 R4 R5 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-357 2 H OCF3 H H 567 1370 1227 
CDE-356 2 H F F F 544 1100 1241 
CDE-359a 2 H H Cl H 974 3373 2084 
CDE-454 2 H H Br H NT 738 607 
CDE-344b 2 H CF3 H H 866 1002 830 
CDE-345b 2 H H CF3 H 539 1469 673 
CDE-330c 2 H CF3 Cl H 115 365 112 
         
CDE-382d 1 H F F F 1371 6097 8553 
CDE-370d 1 H H Cl H 865 497 1079 
CDE-371d 1 H H Br H 1205 742 1188 
CDE-383d 1 H H CF3 H 355 1023 724 
CDE-347c 1 H CF3 Cl H 293 888 309 
         
CDE-373 0 H OCH3 H H >3000 2508 >3000 
CDE-374 0 OCF3 H H H 1155 125 3864 
CDE-387 0 H OCF3 H H 961 462 809 
CDE-376 0 H H OCF3 H 998 320 1447 
CDE-453 0 H F F F NT 1122 854 
CDE-384 0 H F H F 2433 1884 1774 
CDE-390 0 H H F H >3000 4055 >3000 
CDE-361a 0 H H Cl H 851 232 2000 
CDE-360a 0 H H Br H 771 164 1670 
CDE-364a 0 H CF3 H H 533 475 898 
CDE-388 0 H H CF3 H 485 422 526 
CDE-367 0 H CF3 F H 260 367 572 
CDE-348c 0 H CF3 Cl H 240 99 454 
 
R3 R4 R5 Plasma IC50 (µM) 
n=0 n=1 n=2 
F F F NT 1371 544 
H Br H 771 1205 NT 
H Cl H 851 865 974 
CF3 Cl H 240 293 115 
H CF3 H 485 355 539 
aCompound synthesized by Himabindu Anumala. bCompound synthesized by Dan Strien. 
cCompound synthesized by Naga Guntaka.  dCompound synthesized by Sarah Burke NT: not 
tested. 
N
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We synthesized a large number of potential inhibitors according to the above procedure 
and compared the change of tether length of these compounds. From our earlier studies of 
polyphenolic compounds, a 3,4-dihydroxybenzene (catechol) moiety exhibited similar activity to 
galloyl moiety. Therefore, we kept constant the catechol unit in the right hand side and placed 
differently substituted aromatic groups on the left hand side while changing the tether length 
between the carbonyl carbon and catechol unit. According to the comparison table (Table 8-b), 
the para-bromo substituted compound showed varying IC50 values by increasing the chain 
length, that is an inhibitor with no spacer (CDE-360, n=0) exhibited an IC50 of 771 µM in 
plasma, an inhibitor with one methylene spacer (CDE-371, n=1) increased the IC50 value by 
~two-fold (IC50 = 1205 µM) in plasma. The analogous inhibitor with two methylene spacers 
(CDE-454, n=2) showed IC50 of 738 µM in standard buffer and was not tested in plasma due to 
the loss of activity. However, considering the similar series of compounds that are substituted at 
the para position with a CF3 group (CDE-388, CDE-383, CDE-345), all three values for n=0, 1, 
2 showed similar activity, indicating that the length of the spacing unit was irrelevant in this 
series. As shown in Figure 9, we compared IC50 by changing the substitution pattern similar to 
our lead molecule (para-chlorobenzene) and to our standard aromatic substitution (para-chloro-
meta-trifluorobenzene). Compounds in the para-chloro substituted series (CDE-361, CDE-370 
and CDE-359) showed very similar activities of 851 µM, 865 µM, and 974 µM respectively in 
plasma as the tether length was increased.  Counter to this, the series containing the para-chloro 
meta-trifluorobenzene moiety showed a lower IC50 value of 115 µM for n=2 compared to other 
two shorter inhibitors. Ultimately, it appears that any effect due to tether length is dependent on 
the substitution pattern on the aromatic ring. 
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Figure 9: Comparison of tether length 
 
II-4: Effect of changing amide position 
We were also interested in what the effect would be of by changing the orientation of the 
left-hand amide. Instead of containing a benzylamide group, the carbonyl position was relocated 
to the benzylic carbon. Both ester and hydrazide versions were synthesized while adding a chiral 
position from the starting amino acid in two of the analogues, and our collaborators determined 
the IC50 values. Only CDE-401 showed a measureable IC50 value of 2502 µM in a simple buffer 
system, while other compounds did not show any activity at the concentrations used in the assay. 
Due to these higher values, none of the compounds were tested in assays containing 1.5% BSA 
or plasma.   
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Table 9: Change of amide position.  
Code R’ R’’ 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-391 H  NT >1000 NT 
CDE-392 H 
 
NT >3000 NT 
CDE-401 
  
NT 2502 NT 
CDE-393   
NT >3000 NT 
NT: not tested 
   
II-5: Effect of extended versions of lead molecule 
Finally, I wanted to observe the effect on activity of extended versions of the lead 
molecule because I thought that it would be a good comparison to our standard hydrazide 
compound. I held the substitution pattern on aromatic group constant (para-chloro-meta-
trifluorobenzene) and extended the length of the molecule by using different functionalities in 
the R group (Table 10). In those compounds, the shortest version (CDE-431) and longest 
symmetric version (CDE-439) showed similar activity (IC50 ~ 58 µM) to our lead molecule. 
Also, the IC50 versus PAI-1 was increased by increasing the length of the inhibitor (CDE-251, 
CDE-445, and CDE-441 respectively). By contrast, CDE-323 was not tested in plasma due to 
poor solubility and inactivity in standard buffer. 
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Table 10: Extended versions of lead molecule.  
Code R 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-431  56.1 132 86.4 
CDE-251a 
 
108 76 123 
CDE-440 
 
1407 105 2972 
CDE-445 
 
538 108 692 
CDE-441 
 
1199 335 1087 
CDE-323b 
 
NT >100 NT 
CDE-439 
 
58 150 76 
aCompound synthesized by Greg Abernathy. bCompound synthesized by Sarah Burke. NT: not 
tested 
 
 
II-6: Conclusion 
Based upon the above results, the hydrazide analogs with substituted aromatic rings 
possess better inhibitory activity than similarly substituted carboxylic acid and ester analogs. The 
ester analogs are ten- to thirteen-fold less potent than corresponding hydrazide analogs. 
Additionally, 3,4-dihydroxybenzene (catechol moiety) and para-chloro-meta-trifluorobenzene 
are useful in designing potential PAI-1 inhibitors. In molecules containing both of these units, 
there is no predictable impact from changing the tether length between the carbonyl and the 
catechol unit. Also, we found that switching the carbonyl position of the left-hand amide 
destroys PAI-1 inhibitory activity. When considering extended versions of our lead molecule, the 
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longest symmetric compound and its monomer (the shortest molecule) displayed very good 
inhibitory activity in plasma containing assay, displaying IC50 values that were 1.5-fold higher 
than our lead molecule. However, we did not discover any compound that improved the potency 
of our lead molecule, although we did identify functional groups that can generally improve 
activity against PAI-1.  
 
II-7: Experimental methods and data 
Chemistry for general method:  
Unless otherwise noted, all the reactions were performed in 120 ºC oven-dried glassware 
with magnetic stirring. All reagent grade solvents were used without purification for extraction, 
chromatography and reactions. Thin layer chromatography (TLC) was performed with 250 mm 
silica gel coated glass plates from Sorbent Technologies, and visualized with 254 nm UV light 
and/or aqueous KMnO4 solution or ninhydrin solution.  Column chromatography was executed 
using silica gel (Sorbent Technologies Premium Rf; 60 Å, 40-75 µM) as the stationary phase. 
1H 
and 13C NMR spectra were obtained with a JEOL ECX-400 spectrometer with a probe 
temperature of 25 ºC using DMSO-d6 (Cambridge Isotope Laboratories, Inc.) or CDCl3 
(Cambridge Isotope Laboratories, Inc.) as solvents. Chemical shifts were measured relative to 
the tetramethylsilane (TMS) peak and were recorded in δ (parts per million, ppm). The internal 
references were DMSO-d6 (δ = 2.50 ppm) for 1H NMR and DMSO-d6 (δ = 39.5 ppm) for 13C 
NMR; CDCl3 (δ = 7.26 ppm) for 1H NMR and CDCl3 (δ = 77.0 ppm) for 13C NMR. Coupling 
constants (J) are recorded in Hertz. Splitting patterns are labeled as follows: bs, broad singlet; s, 
singlet; d, doublet; t, triplet; q, quartet; p, pentet; m, multiplet. High-resolution mass 
spectroscopy data were provided by Prof. Ruth Ann Armitage, Eastern Michigan University, 
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Ypsilanti, MI, and were recorded using Direct Analysis in Real Time (DART) on a JEOL 
AccuTOF DART instrument, JEOL USA, Inc., Peabody, Massachusetts. 
 
Synthetic procedures: 
 
Ethyl 2-oxo-2-((3-(trifluoromethyl)benzyl)amino)acetate [DAW-1-9] 
A solution of 3-(trifluromethyl)benzylamine (215 µl, 1.5 mmol), pyridine (364 µl, 4.5 mmol) and 
methylene chloride (6 ml) was cooled in an ice bath. Ethyl chlorooxoacetate (167 µl, 1.5 mmol) 
was added and the resulting solution was stirred 48 hours. The reaction mixture was diluted with 
≈30 ml of ethyl acetate and washed with 0.2N HCl (2x) and saturated NaHCO3 (2x), dried with 
MgSO4, filtered, and concentrated in vacuo to obtain 0.3902 g (94.5%) of DAW-1-9 as a thick 
oil. 1H NMR (CDCl3, 400 MHz) δ 7.56 (m, 2H), 7.48 (m, 3H), 4.57 (d, J=5.9 Hz, 2H), 4.36 (q, 
J=7.3 Hz, 2H), 1.39 (t, J=7.4 Hz, 3H). 
 
 
2-Hydrazinyl-2-oxo-N-(trifluoromethyl)benzyl)acetamide [DAW-1-12 (CDE-297)] 
To a mixture of DAW-1-9 (110.1 mg, 0.41 mmol) in ethanol (4.2 ml) was added hydrazine 
hydrate (~50% solution with H2O, 53.7 µl, 0.84 mmol). The milky reaction mixture was stirred 
overnight, filtered, and the solid was dried in vacuo to provide 0.1010g (94%) of DAW-1-12 as a 
white solid. 1H NMR (DMSO-d6, 400MHz) δ 10.04 (s, 1H), 9.36 (t, J= 6.4 Hz, 1H), 7.55 (m, 
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4H), 4.51 (bs, 2H), 4.35 (d, J=6.8 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 160.55, 158.43, 
140.85, 132.07, 129.90, 129.52 (q, J= 30.5 Hz), 124.76 (J=270.7 Hz), 124.41 (q, J=3.81 Hz), 
124.19 (q, J=37.7 Hz); HRMS, DART calcd. for C10H11F3N3O2 [M+H]
+ 262.08033, found: 
262.07901. 
 
Ethyl 2-oxo-2-((3,4,5-trifluorobenzyl)amino)acetate [DAW-1-13] 
The solution of 3,4,5-trifluorobenzylamine (172.5 µl, 1.5 mmol), pyridine (364 µl, 4.5 mmol) 
and methylene chloride (6 ml) was cooled in an ice bath. Ethyl chlorooxoacetate (167 µl, 1.5 
mmol) was added and the resulting yellow solution was stirred for 48 hours. The reaction 
mixture was diluted with ≈30 ml of ethyl acetate and washed with 0.2N HCl (2x) and saturated 
NaHCO3 (2x), dried with MgSO4, filtered, and concentrated in vacuo to obtain 0.3192 g (81.5%) 
of DAW-1-13 as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 7.47 (bs, 1H), 6.92 (m, 2H), 4.44 
(d, J=6.4 Hz, 2H), 4.36 (q, J=7.3 Hz, 2H), 1.39 (t, J=6.9 Hz, 3H). 
 
 
2-Hydrazinyl-2-oxo-N-(3,4,5-trifluorobenzyl)acetamide [DAW-1-15 (CDE-304)] 
To a mixture of DAW-1-13 (104.9 mg, 0.40 mmol) in ethanol (4.2 ml), hydrazine hydrate (~50% 
solution with H2O, 53.8 µl, 0.84 mmol) was added. The off-white reaction mixture was stirred 
for 48 hours, filtered, and the solid was dried in vacuo to provide 0.0537 g (54.3%) of DAW-1-
15 as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 10.02 (bs, 1H), 9.36 (t, J= 6.4 Hz, 1H), 
7.15 (m, 2H), 4.50 (bs, 2H), 4.25 (d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 160.62, 
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158.31, 150.55 (ddd, J=245.1 Hz, J=9.5 Hz, J=3.8 Hz), 138.19 (dt, J=246 Hz, J=15.3 Hz), 
136.79 (ddd, J=6.7 Hz, J=7.6 Hz, J=3.8Hz), 112.33 (dt, J=20.0 Hz, J=4.8 Hz), 41.73 ; HRMS, 
DART calcd. for C9H9F3N3O2 [M+H]
+ 248.06468, found: 248.06619. 
 
 
Ethyl 2-((4-cyanobenzyl)amino)-2-oxoacetate [DAW-1-26 (CDE-319)] 
A mixture of 4-cyanobenzylamine hydrochloride (253.7 mg, 1.5 mmol), pyridine (365 µl, 4.5 
mmol) and methylene chloride (6 ml) was cooled in an ice bath. Ethyl chlorooxoacetate (167 µl, 
1.5 mmol) was added and the resulting solution was stirred 48 hours. The reaction mixture was 
filtered. The filtrate was diluted with ≈30 ml of ethyl acetate and washed with 0.2N HCl (2x) and 
saturated NaHCO3 (2x), dried with MgSO4, filtered, and concentrated in vacuo to obtain 0.2467 
g (70.8%) of DAW-1-26 as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.63 (m, 2H), 7.48 (bs, 
1H), 7.40 (m, 2H), 4.57 (d, J=6.4 Hz, 2H), 4.36 (q, J=7.3 Hz, 2H), 1.39 (t, J=7.4 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz) δ 160.48, 156.86, 142.28, 132.69, 128.51, 118.55, 111.93, 63.61, 
43.42, 14.05. HRMS, DART calcd. for C12H13N2O3 [M+H]
+ 233.09262, found: 233.09190. 
 
 
N- (4-cyanobenzyl)-2-hydrazinyl-2-oxoacetamide [DAW-1-52 (CDE-336)] 
To a mixture of DAW-1-26 (99.5 mg, 0.43 mmol) in ethanol (4.2 ml), hydrazine hydrate (~50% 
solution with H2O, 53.70 µl, 0.84 mmol) was added. The milky reaction mixture was stirred 
overnight, filtered, and the solid was dried in vacuo to provide 0.0781g (83.2%) of DAW-1-52 as 
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a white solid. 1H NMR (DMSO-d6, 400MHz) δ 10.27 (bs, 1H), 9.35 (t, J= 6.4 Hz, 1H), 7.74 (d, 
J=8.2 Hz, 2H), 7.39(d, J=8.3 Hz, 2H),  4.50 (s, 2H), 4.35 (d, J=6.4 Hz, 2H); 13C NMR (DMSO-
d6, 100 MHz) δ 160.61, 158.37, 145.15, 132.80, 128.65, 119.37, 110.20, 42.53; HRMS, DART 
calcd. for C10H11N4O2 [M+H]
+ 219.08819, found: 219.08740. 
 
2-Oxo-2-((3-(trifluoromethyl)benzyl)amino)acetic acid [DAW-1-21 (CDE-311)] 
A solution of DAW-1-9 (237.1 mg, 0.86 mmol), 1 M NaOH (4 ml), H2O (4 ml), and ethanol (8 
ml) was stirred for 15 minutes. The reaction mixture was monitored by TLC (70% ethyl acetate : 
30% hexane mobile phase) and the resulting solution was quenched with 1N HCl (12 ml) and 
allowed to cool in an ice bath for 1.5 hours, forming a precipitate. The solid was filtered and 
dried to provide 0.1603 g (75.4%) of DAW-1-21 as a white solid. 1H NMR (DMSO-d6, 
400MHz) δ 9.42 (t, J=5.9 Hz, 1H), 7.56 (m, 4H), 4.36 (d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 
100 MHz) δ 162.49, 159.10, 140.57, 132.07, 129.96, 129.56 (q, J=30.5 Hz), 124.76 (q, J=270.8 
Hz), 124.45 (q, J=3.8 Hz), 124.27 (q, J=3.2 Hz), 42.56; HRMS, DART calcd. for C10H9F3NO3 
[M+H]+ 248.05345, found: 248.05170. 
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2-(2-(tert-Butyl)hydrazinyl)-2-oxo-N-(3-(trifluoromethyl)benzyl)acetamide [DAW-1-24 
(CDE-310)] 
To a mixture of DAW-1-21 (100.3 mg, 0.406 mmol), tert-butylhydrazine hydrochloride (60.5 
mg, 0.486 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (76.1 mg, 0.486 mmol), and N-
methylmorpholine [NMM] (53.5µl, 0.486 mmol) in methylene chloride (4 ml), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (93.1 mg, 0.486 mmol) was 
added and stirred overnight. The reaction mixture was monitored by TLC (50% ethyl acetate: 
50% hexane mobile phase) and the resulting solution was diluted with ≈20 ml of ethyl acetate 
and washed with 1N HCl (2x), saturated NaHCO3 (2x), and brine solution, dried with MgSO4, 
filtered, and concentrated in vacuo to obtain 0.0639 g (49.6%) of DAW-1-24 as a white solid. 1H 
NMR (CDCl3, 400 MHz) δ 8.53 (bs, 1H), 7.72 (bs, 1H), 7.56 (m, 2H), 4.55 (d, J=5.9 Hz, 2H), 
4.47 (bs, 1H), 1.13 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ159.50, 157.92. 137.97, 131.24 (q, 
J=32.4 Hz), 131.22, 129.38, 124.78 (q, J=3.8 Hz), 124.65 (q, J=3.8 Hz), 123.97 (q, J=270.8 Hz), 
55.70, 43.17, 27.20;   HRMS, DART calcd. for C14H19F3N3O2 [M+H]
+ 318.14293, found: 
318.14240. 
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2-((4-Chloro-3-(trifluoromethyl)benzyl)amino)-2-oxoacetic acid [DAW-1-30] 
A solution of ethyl 2-oxo-2-((4-chloro-3-(trifluoromethyl)benzyl)amino)acetate [GA-III-88] 
(1.2757 g, 4.128 mmol), 1 M NaOH (16.5 ml), H2O (16.5 ml), and ethanol (33 ml) was stirred 
for 15 minutes. The reaction mixture was monitored by TLC (70% ethyl acetate : 30% hexane 
mobile phase) and the resulting solution was quenched with 1 N H HCl (49.5 ml) and allowed to 
cool in an ice bath for 45 minutes, forming a precipitate. The solid was filtered and dried to 
provide 1.1967 g (quantitative yield) of DAW-1-30 as a white solid. 1H NMR (DMSO-d6, 
400MHz) δ 9.42 (t, J=5.9 Hz, 1H), 7.73 (d, J=1.8 Hz, 1H), 7.65 (d, J=8.2 Hz, 1H), 7.54 (dd, 
J=6.4 Hz, J=1.8 Hz, 1H), 7.34 (d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 162.38, 
159.10, 139.26, 133.70, 132.15, 129.70 (q, J=1.9 Hz), 127.39 (q, J=4.77 Hz), 126.95 (q, J=30.5 
Hz), 123.4 (q, J=271.73 Hz), 42.09. 
 
 
2-(2-(3-Bromobenzoyl)hydrazinyl)-N-(4-chloro-3-(trifluoromethyl)benzyl)-2-oxoacetamide 
[DAW-1-33 (CDE-333)] 
To a mixture of DAW-1-30 (100.5 mg, 0.357 mmol), 3-bromobenzoic hydrazide (93.2 mg, 0.426 
mmol), 1-hydroxybenzotriazole [HOBt•H2O] (66.1 mg, 0.426 mmol), N-methylmorpholine 
[NMM] (47.0µl, 0.426 mmol) in methylene chloride (4 ml), 1-ethyl-3-(3-
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dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (83.0 mg, 0.426 mmol) was 
added and stirred for four days. The reaction mixture was filtered and the filtrate was diluted 
with ≈20 ml of ethyl acetate and washed with 1N HCl (2x), saturated NaHCO3 (2x), and brine 
solution, and concentrated in vacuo to obtain 0.0365 g (21.3%) of DAW-1-33 as a yellow solid. 
1H NMR (DMSO-d6, 400 MHz) δ 10.77 (bs, 1H), 10.64 (bs, 1H), 9.51 (t, J=4.5 Hz, 1H), 8.01(m, 
1H), 7.84 (m, 1H), 7.76 (s, 1H), 7.68 (m, 2H), 7.57 (m, 1H), 4. 38 (d, J=13.3 Hz); 13C NMR 
(DMSO-d6, 100 MHz) δ 164.83, 160.36, 158.38, 139.41, 134.70, 133.78, 132.19, 
131.19,130.60,129.72, 127.84 (q, J=43.8 Hz), 127.36 (q, J=6.6 Hz), 127.07 (q, J=6.6 Hz), 
123.39 (q, J=271.7 Hz), 122.19, 120.32, 42.00; HRMS, DART calcd. for C17H13BrClF3N3O3 
[M+H]+ 477.97810, found: 477.97821. 
 
N1-(4-Chloro-3-(trifluoromethyl)benzyl)-N2-methoxyoxalamide [DAW-1-34 (CDE-320)] 
To a mixture of DAW-1-30 (103.8 mg, 0.369 mmol), methoxyamine hydrochloride (36.9 mg, 
0.426 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (65.8 mg, 0.426 mmol), N-
methylmorpholine [NMM] (47.0µl, 0.426 mmol) in methylene chloride (4 ml), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (82.4 mg, 0.426 mmol) was 
added and stirred for four days.  The reaction mixture was monitored by TLC(50% ethyl acetate: 
50% hexane mobile phase) and the resulting solution was diluted with ≈20 ml of ethyl acetate 
and washed with 1N HCl (2x), saturated NaHCO3 (2x), and brine solution, dried with MgSO4, 
filtered, and concentrated in vacuo to obtain 0.0541 g (47.2%) of DAW-1-34 as a white solid. 1H 
NMR (DMSO-d6, 400 MHz) δ 12.11 (bs, 1H), 9.45 (t, J=5.9 Hz, 1H), 7.73 (d, J=1.8 Hz, 1H), 
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7.65 (d, J=8.2 Hz, 1H), 7.53 (dd, J=6.8 Hz, J=1.4 Hz, 1H), 4.33 (d, J=6.4 Hz, 2H), 3.59 (s, 3H); 
13C NMR (DMSO-d6, 100 MHz) δ 160.17, 156.99, 139.26, 133.78, 132.16, 129.70, 127.52 (q, 
J=4.77 Hz), 126.92 (q, J=31.46 Hz), 223.38 (q, J=270.8 Hz), 63.67, 41.83; HRMS, DART calcd. 
for C11H11ClF3N2O3 [M+H]
+ 311.04103, found: 311.03891. 
 
 
N-(4-Chloro-3-(trifluoromethyl)benzyl)-2-oxo-2-(2-(phenylsulfonyl)hydrazinyl)acetamide 
[DAW-1-38 (CDE-334)] 
To a mixture of DAW-1-30 (100.4 mg, 0.3565 mmol), benzenesulfonyl hydrazide (74.2 mg, 
0.4263 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (66.2 mg, 0.426 mmol), N-
methylmorpholine [NMM] (47.0µl, 0.426 mmol) in methylene chloride (4 ml), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (82.3 mg, 0.426 mmol) was 
added and stirred overnight.  The yellow reaction mixture was monitored by TLC (50% ethyl 
acetate: 50% hexane mobile phase) and the resulting solution was diluted with ≈20 ml of ethyl 
acetate and washed with 1N HCl (2x), saturated NaHCO3 (2x), and brine solution (2x), dried 
with MgSO4, filtered, and concentrated in vacuo to obtain 0.0563 g (36.3%) of DAW-1-38 as a 
white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.84 (d, J=2.3 Hz, 1H), 10.01 (d, J=2.7 Hz, 1H), 
9.38 (t, J=5.9Hz, 1H), 7.78 (m, 3H), 7.57 (m, 5H), 4.28 (d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 
100 MHz) δ 159.65, 159.61, 139.75, 139.16, 133.69, 133.57, 132.16, 129.73, 129.38, 128.05, 
127.34 (q, J=4.7 Hz), 126.95 (q J=30.5 Hz), 123.36 (q J=271.7 Hz), 41.87 ; HRMS, DART 
calcd. for C16H14ClF3N3O4S [M+H]
+ 436.03456, found: 436.03448. 
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N1-(4-Chloro-3-(trifluoromethyl)benzyl)-N2-(3-phenylpropyl)oxalamide [DAW-1-39 (CDE-
335)] 
To a mixture of DAW-1-30 (101.6 mg, 0.361 mmol), 3-phenyl-1-propylamine (60.5 µl, 0.426 
mmol), 1-hydroxybenzotriazole [HOBt•H2O] (66.6 mg, 0.426 mmol), N-methylmorpholine 
[NMM] (47.0µl, 0.426 mmol) in methylene chloride (4 ml), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (82.1 mg, 0.426 mmol) was 
added and stirred overnight.  The brown reaction mixture was monitored by TLC (50% ethyl 
acetate: 50% hexane mobile phase) and the resulting solution was diluted with ≈20 ml of ethyl 
acetate and washed with 1N HCl (2x), saturated NaHCO3 (2x), and brine solution (2x), and 
concentrated in vacuo to obtain 0.1285 g (89.3%) of DAW-1-39 as a white solid. 1H NMR 
(CDCl3, 400 MHz) δ 7.97 (t, J=20.6 Hz, 1H), 7.59 (d, J=1.3 Hz, 1H), 7.43 (m, 3H), 7.27 (m, 
3H), 4.48 (d, J=6.4 Hz, 2H), 3.33 (q, J=6.84 Hz, 2H), 2.66 (t, J=7.3 Hz, 2H), 1.90 (p, J=7.3 Hz, 
2H); 13C NMR (DMSO-d6, 100 MHz) δ 160.96,160.29, 142.08, 139.47, 133.75, 132.13, 129.66, 
128.78, 127.46 (q, J=4.8 Hz), 126.85 (q, J=30.5 Hz), 126.26, 123.39 (q, J=270.8 Hz), 42.05, 
39.16, 33.02, 30.89; HRMS, DART calcd. for C19H19ClF3N2O2 [M+H]
+ 399.10872, found: 
399.10779. 
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N-(4-Chloro-3-(trifluoromethyl)benzyl)-3-(4-hydroxyphenyl)propanamide [DAW-1-62 
(CDE-354)] 
To a mixture of 3-(4-hydroxyphenyl)propanoic acid (182.9 mg, 1.097 mmol), 4-chloro-3-
(trifluoromethyl)benzylamine (200 µl, 1.316 mmol), 1-hydroxybenzotriazole [HOBt•H2O] 
(201.8 mg, 1.316 mmol), N-methylmorpholine [NMM] (145 µl, 1.316 mmol) in methylene 
chloride (5 ml) in an ice bath, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
[EDC•HCl] (252.4 mg, 1.316 mmol) was added. The mixture was dissolved by adding 
dimethylformamide [DMF] (2 ml) and was stirred overnight.  The yellow reaction mixture was 
reduced in volume in vacuo and the resulting solution was diluted with ≈15 ml of 4:1 of ethyl 
acetate:hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (2x), 
dried over MgSO4, and concentrated in vacuo to obtain 0.1623 g of DAW-1-62 as a dark yellow 
oil. The product was triturated with CHCl3 to obtain 0.1090 g (27.8%) of pure DAW-1-62 as an 
off-white powder. 1H NMR (DMSO-d6, 400 MHz) δ 9.11 (s, 1H), 8.36 (t, J=5.8 Hz, 1H), 7.66 (s, 
1H), 7.57 (d, J=8.2 Hz, 1H), 7.31 (d, J=7.3 Hz, 1H), 6.93 (d, J=8.2 Hz, 2H), 6.60 (d, J=8.2 Hz, 
2H), 4.26 (d, J=5.9 Hz, 2H), 2.68 (t, J=7.4 Hz, 2H), 2.36 (t, J=7.3 Hz, 2H); 13C NMR (DMSO-
d6, 100 MHz) δ 172.31, 156.02, 140.46, 133.28, 131.95, 131.67, 129.62, 129.30, 127.03 (q, 
J=4.7 Hz), 126.87 (q, J=30.5 Hz), 123.41 (q, J=271.7 Hz) 115.54, 41.57, 37.85, 30.76; HRMS, 
DART calcd. for C17H16ClF3NO2 [M+H]
+ 358.08217, found: 358.08139. 
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N-(4-Chloro-3-(trifluoromethyl)benzyl)-3-(3,4-dichlorophenyl)propanamide [DAW-1-64 
(CDE-355)] 
To a mixture of 3-(3,4-dichlorophenyl)propanoic acid (240.8 mg, 1.097 mmol), 4-chloro-3-
(trifluoromethyl)benzylamine (200 µl, 1.316 mmol), 1-hydroxybenzotriazole [HOBt•H2O] 
(201.7 mg, 1.316 mmol), N-methylmorpholine [NMM] (145 µl, 1.316 mmol) in methylene 
chloride (5 ml) in an ice bath, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
[EDC•HCl] (252.3 mg, 1.316 mmol) was added. The mixture was dissolved by adding 
dimethylformamide [DMF] (2 ml) and stirred overnight.  The yellow reaction mixture was 
reduced in volume in vacuo and the resulting solution was diluted with ≈25 ml of 4:1 of ethyl 
acetate: hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), 
dried over MgSO4, and concentrated in vacuo to obtain 0.240 g of DAW-1-64 as a yellow solid. 
The product was triturated with CHCl3 to obtain 0.1825 g (40.5%) of pure DAW-1-64 as a white 
powder. 1H NMR (DMSO-d6, 400 MHz) δ 8.41 (t, J=5.5 Hz, 1H), 7.61 (d, J=1.8 Hz, 1H), 7.56 
(d, J=8.2 Hz, 1H), 7.43 (d, J=8.2 Hz, 1H), 7.41 (d, J=1.8 Hz, 1H), 7.35 (dd, J=8.2 Hz, J=1.4 Hz, 
1H), 7.14 (dd, J=8.3 Hz, J=2.3 Hz, 2H), 4.26 (d, J=5.9 Hz, 2H), 2.80 (t, J=7.3 Hz, 2H), 2.44 (t, 
J=7.3 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 171.71, 142.89, 14350., 133.28, 131.93, 
131.25, 130.86, 130.75, 129.34, 129.05, 127.05 (q, J=4.7 Hz), 126.92 (q, J=34.3 Hz), 123.36 (q, 
J=271.7 Hz), 41.60, 36.62, 30.37; HRMS, DART calcd. for C17H14Cl3F3NO [M+H]
+ 410.00932, 
found: 410.00809. 
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3-(3,4-Dihydroxyphenyl)-N-(3,4,5-trifluorobenzyl)propanamide [DAW-1-66 (CDE-356)] 
To a mixture of 3,4,5-trifluorobenzylamine (201.8 µl, 1.647 mmol), 3-(3,4-
dihydroxyphenyl)propanoic acid (250.5 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] 
(252.9 mg, 1.647 mmol), N-methylmorpholine [NMM] (182.25 µl, 1.647 mmol) in methylene 
chloride (5 ml) in an ice bath, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
[EDC•HCl] (316.2 mg, 1.647 mmol) was added. The mixture was dissolved by adding 
dimethylformamide [DMF] (2 ml) and stirred overnight.  The dark yellow reaction mixture was 
reduced in volume in vacuo and the resulting solution was diluted with ≈25 ml of 4:1 of ethyl 
acetate: hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), 
dried over MgSO4, and concentrated in vacuo to obtain 0.4753 g of DAW-1-66 as a brown oil. 
The product was triturated with CHCl3 to obtain 0.4645 g (100%) of pure DAW-1-66 as a brown 
paste. 1H NMR (DMSO-d6, 400 MHz) δ 8.64 (s, 1H), 8.57 (s, 1H), 8.32 (t, J=5.9 Hz, 1H), 7.03 
(m, 2H), 6.57 (m, 2H), 6.38 (dd, J=7.8 Hz, J=1.8 Hz, 1H), 4.18 (d, J=5.9 Hz, 2H), 2.62 (t, J=7.8 
Hz, 2H), 2.34 (t, J=7.3 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 172.38, 150.57 (ddd, 
J=246.0 Hz, J=9.5 Hz, J=3.8 Hz,), 145.52, 143.91, 137.94 (dt, J=245.0 Hz, J=16.2 Hz), 132.42, 
119. 24, 116.20, 115.85, 111.94, 111.74, 41.44, 37.80, 30.92; HRMS, DART calcd. for 
C16H15F3NO3 [M+H]
+ 326.10042, found: 326.08871. 
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3-(3,4-Dihydroxyphenyl)-N-(3-(trifluoromethoxy)benzyl)propanamide [DAW-1-68 (CDE-
357)] 
To a mixture of 3-(triflouromethoxy)benzylamine (250 µl, 1.647 mmol), 3-(3,4-
dihydroxyphenyl)propanoic acid (250.4 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] 
(253.2 mg, 1.647 mmol), N-methylmorpholine [NMM] (182.25 µl, 1.647 mmol) in methylene 
chloride (5 ml) in an ice bath, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
[EDC•HCl] (316.2 mg, 1.647 mmol) was added. The mixture was dissolved by adding 
dimethylformamide [DMF] (2 ml) and stirred overnight.  The brown reaction mixture was 
reduced in volume in vacuo and the resulting solution was diluted with ≈25 ml of 4:1 of ethyl 
acetate: hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), 
dried over MgSO4, and concentrated in vacuo to obtain DAW-1-68 as a brown oil. The product 
was triturated with CHCl3 to obtain 0.2964 g (60.8%) of pure DAW-1-68 as a white powder. 
1H 
NMR (DMSO-d6, 400 MHz) δ 8.62 (bs, 2H), 8.34 (t, J=5.9 Hz, 1H), 7.37 (dd, J=8.2 Hz, J=7.8 
Hz, 1H), 7.16 (m, 2H), 7.10 (d, J=7.8 Hz, 1H), 6.56 (m, 2H), 6.39 (dd, J=8.2 Hz, J=1.8 Hz, 1H), 
4.25 (d, J=5.9 Hz, 2H), 2.62 (t, J=7.32 Hz, 2H), 2.33 (t, J=7.4 Hz, 2H); 13C NMR (DMSO-d6, 
100 MHz) δ 172.25, 148.90, 145.53, 143.88, 143.15, 132.51, 130.70, 126.62, 120.61 (q, J=254.6 
Hz), 119.96, 119.62, 119.27, 116.67, 115.92, 41.91, 37.96, 31.08; HRMS, DART calcd. for 
C17H17F3NO4[M+H]
+ 356.11097, found: 356.10101. 
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N-(4-Fluoro-3-(trifluoromethyl)benzyl)-3,4-dihydroxybenzamide [DAW-1-72 (CDE-367)] 
To a mixture of 4-fluoro-3-(trifluoromethyl)benzylamine (323.9mg, 1.647 mmol), 3,4-
dihydroxybenzoic acid (211.8 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (252.9 
mg, 1.647 mmol), N-methylmorpholine [NMM] (180.0 µl, 1.647 mmol) in methylene chloride (5 
ml) in an ice bath, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] 
(317.5 mg, 1.647 mmol) was added. The mixture was dissolved by adding dimethylformamide 
[DMF] (2 ml) and stirred overnight.  The yellow reaction mixture was reduced in volume in 
vacuo and the resulting solution was diluted with ≈25 ml of 4:1 of ethyl acetate: hexane and 
washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), dried over MgSO4, 
and concentrated in vacuo to obtain 0.438 g of DAW-1-72 as a yellow solid. The product was 
triturated with CHCl3 to obtain 0.226 g (50.0%) of pure DAW-1-72 as a yellow solid. 
1H NMR 
(DMSO-d6, 400 MHz) δ 9.46 (s, 1H), 9.10 (s, 1H), 8.76 (t, J=5.9 Hz, 1H), 7.62 (m, 2H), 7.41 
(dd, J=10.5 Hz, J=8.7 Hz, 1H), 7.27 (d, J=2.3 Hz, 1H), 7.18 (dd, J=8.2 Hz, J=2.3 Hz, 1H), 6.73 
(d, J=8.2 Hz, 1H), 4.42 (d, J=5.9 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 166.78, 158.26 
(dq, J=250.8 Hz, J=1.9 Hz), 149.10, 145.43, 137.83 (d, J=3.8 Hz), 134.54 (d, J=8.6 Hz), 126.35 
(q, J=4.8 Hz), 125.78, 123.23 (qd, J=269.8 Hz, J=9.5 Hz), 119.56, 117.56 (d, J=20.0 Hz), 116.65 
(qd, J=32.4 Hz, J=12.4 Hz), 115.63, 42.11 ; HRMS, DART calcd. for C15H12F4NO3[M+H]
+ 
330.07533, found: 330.06400. 
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3,4-Dihydroxy-N-(3-methoxybenzyl)benzamide [DAW-1-74 (CDE-373)] 
To a mixture of 3-methoxybenzylamine (220 µl, 1.647 mmol), 3,4-dihydroxybenzoic acid (211.5 
mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (251.7 mg, 1.647 mmol), N-
methylmorpholine [NMM] (181 µl, 1.647 mmol) in methylene chloride (5 ml) in an ice bath, 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (316.6 mg, 1.647 
mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred overnight.  The light brown reaction mixture was diluted with ≈25 ml of 4:1 of ethyl 
acetate: hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), 
dried over MgSO4, and concentrated in vacuo to obtain 0.1259 g of DAW-1-74 as a yellow 
crystals. The product was triturated with CHCl3 to obtain 0.0694 g (18.5%) of pure DAW-1-74 
as a yellow crystals. 1H NMR (DMSO-d6, 400 MHz) δ 9.40 (bs, 1H), 9.09 (bs, 1H), 8.63 (t, 
J=5.9 Hz, 1H), 7.27 (d, J=2.28 Hz, 1H), 7.18 (m, 2H), 6.81 (m, 2H), 6.73 (m, 2H), 4.35 (d, J=5.9 
Hz, 2H), 3.39 (s, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 166.64, 159.78, 148.93, 145.38, 
142.25, 129.80, 126.15, 119.84, 119.51, 115.40, 113.42, 112.39, 55.47, 42.94; HRMS, DART 
calcd. for C15H16NO4 [M+H]
+ 274.10792, found: 274.10089. 
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3,4-Dihydroxy-N-(2-(trifluoromethoxy)benzyl)benzamide [DAW-1-76 (CDE-374)] 
To a mixture of 2-(trifluoromethoxy)benzylamine (246.25 µl, 1.647 mmol), 3,4-
dihydroxybenzoic acid (211.4 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (252.9 
mg, 1.647 mmol), N-methylmorpholine [NMM] (181 µl, 1.647 mmol) in methylene chloride (5 
ml) in an ice bath, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] 
(315.8 mg, 1.647 mmol) was added. The mixture was dissolved by adding dimethylformamide 
[DMF] (2 ml) and stirred overnight.  The light brown reaction mixture was diluted with ≈25 ml 
of 4:1 of ethyl acetate: hexane and washed with 0.1N HCl (2x). The aqueous layer was washed 
with saturated NaHCO3 (2x), and a white solid formed, which was filtered and dried under 
vacuum to obtain 0.1226 g (27.3%) of DAW-1-76 as a white solid. 1H NMR (DMSO-d6, 400 
MHz) δ 8.60 (bs, 1H), 7.33 (m, 4H), 7.23 (d, J=1.8 Hz, 1H), 7.16 (dd, J=8.2 Hz, J=2.3 Hz, 1H), 
6.63 (d, J=8.2 Hz, 1H), 5.58 (bs, 2H), 4.44 (s, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 167.08, 
151.07, 146.57, 146.34, 132.97, 129.49, 128.94, 127.96, 124.46, 121.09, 120.81 (q, J=255.5 Hz), 
119.48, 115.31, 115.02, 37.52; HRMS, DART calcd. for C15H13F3NO4 [M+H]
+ 328.07966, 
found: 328.07040. 
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3,4-Dihydroxy-N-(4-(trifluoromethoxy)benzyl)benzamide [DAW-1-78 (CDE-376)] 
To a mixture of 4-(trifluoromethoxy)benzylamine (251.5 µl, 1.647 mmol), 3,4-dihydroxybenzoic 
acid (211.6 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (252.2 mg, 1.647 mmol), N-
methylmorpholine [NMM] (181 µl, 1.65 mmol) in methylene chloride (5 ml) in an ice bath, 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (315.8 mg, 1.647 
mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred overnight.  The brown reaction mixture was diluted with ≈25 ml of 4:1 of ethyl acetate: 
hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), dried 
over MgSO4, and concentrated in vacuo to obtain 0.2477 g of DAW-1-78 as a white solid. The 
product was triturated with CHCl3 to obtain 0.2271 g (50.6%) of pure DAW-1-78 as a grey 
crystals. 1H NMR (DMSO-d6, 400 MHz) δ 9.29 (bs, 1H), 8.71 (t, J=5.9 Hz, 1H), 7.36 (d, J=8.9 
Hz, 2H), 7.26 (m, 3H), 7.20 (dd, J=8.2 Hz, J=2.3 Hz, 1H), 6.72 (d, J=8.3 Hz, 1H), 4.39 (d, J=5.3 
Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 166.68, 149.03, 147.59, 145.41, 140.18, 129.48, 
125.93, 121.41, 120.66 (q, J=258.4 Hz), 119.53, 115.66, 115.39, 42.38; HRMS, DART calcd. for 
C15H13F3NO4 [M+H]
+ 328.07966, found: 328.06619. 
 
HO
N
H
O
DAW-1-78 (CDE-376)
NH2
HO
OH
O
OH
OHF3CO F3CO
HOBt, NMM
CH2Cl2
0ºC RT
EDC·HCl
DMF
51 
 
 
 
N-(3,5-Difluorobenzyl)-3,4-dihydroxybenzamide [DAW-1-80 (CDE-384)] 
To a mixture of 3,5-difluorobenzylamine (195.0 µl, 1.647 mmol), 3,4-dihydroxybenzoic acid 
(211.6 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (252.4 mg, 1.647 mmol), N-
methylmorpholine [NMM] (181 µl, 1.65 mmol) in methylene chloride (5 ml) in an ice bath, 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (315.8 mg, 1.647 
mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred overnight.  The brown reaction mixture was diluted with ≈25 ml of 4:1 of ethyl acetate: 
hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), dried 
over MgSO4, and concentrated in vacuo to obtain 0.2035 g of DAW-1-80 as a white solid. The 
product was triturated with CHCl3 to obtain 0.1685 g (44%) of pure DAW-1-80 as a grey 
powder. 1H NMR (DMSO-d6, 400 MHz) δ 9.30 (s, 2H), 8.74 (t, J=5.9 Hz, 1H), 7.28 (d, J=1.8 
Hz, 1H), 7.21 (dd, J=8.2 Hz, J=1.8 Hz, 1H), 7.03 (t, J=9.6 Hz, 1H), 6.94 (d, J=6.4 Hz, 2H), 6.73 
(d J=8.3 Hz, 1H), 4.38 (d, J=5.9 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 166.84, 162.87 (dd, 
J=231.6 Hz, J=13.4Hz), 149.13, 145.55 (t, J=8.5 Hz), 145.44, 125.73, 119.60, 115.63, 115.44, 
110.54 (dd, J=19.07 Hz, J=6.7 Hz), 102.54 (t, J=25.71 Hz), 42.45; HRMS, DART calcd. for 
C14H12F2NO3 [M+H]
+ 280.07853, found: 280.06491. 
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3,4-Dihydroxy-N-(3-(trifluoromethoxy)benzyl)benzamide [DAW-1-70/ 82 (CDE-387)] 
To a mixture of 3-(trifluoromethoxy)benzylamine (247.0 µl, 1.647 mmol), 3,4-dihydroxybenzoic 
acid (211.8 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (252.9 mg, 1.647 mmol), N-
methylmorpholine [NMM] (181.0 µl, 1.647 mmol) in methylene chloride (5 ml) in an ice bath, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (315.8 mg, 1.647 
mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred overnight.  The brown reaction mixture was diluted with ≈25 ml of 4:1 of ethyl acetate: 
hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), dried 
over MgSO4, and concentrated in vacuo to obtain 0.3098 g of DAW-1-82 as a white solid. The 
product was triturated with CHCl3 to obtain 0.257 g (57.3%) of pure DAW-1-82 as a white 
powder. 1H NMR (DMSO-d6, 400 MHz) δ 9.30 (s, 2H), 8.74 (t, J=5.9 Hz, 1H), 7.41 (t, J=8.2 Hz, 
1H), 7.22 (m, 5H), 6.73 (d, J=8.2 Hz, 1H), 4.43 (d, J=5.5 Hz, 2H); 13C NMR (DMSO-d6, 100 
MHz) δ 166.79, 149.06, 148.96, 145.43, 143.62, 130.69, 126.69,125.89, 120.61 (q, J=255.5 Hz), 
119.95, 119.57, 119.54, 115.63, 115.42, 42.54; HRMS, DART calcd. for C15H13F3NO4 [M+H]
+ 
328.07966, found: 328.07059. 
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3,4-Dihydroxy-N-(4-(trifluoromethyl)benzyl)benzamide [DAW-1-84 (CDE-388)] 
To a mixture of 4-(trifluoromethyl)benzylamine (235.0 µl, 1.647 mmol), 3,4-dihydroxybenzoic 
acid (211.7 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (252.9 mg, 1.647 mmol), N-
methylmorpholine [NMM] (181.0 µl, 1.647 mmol) in methylene chloride (5 ml) in an ice bath, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (315.9 mg, 1.647 
mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred overnight.  The brown reaction mixture was diluted with ≈25 ml of 4:1 of ethyl acetate: 
hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), dried 
over MgSO4, and concentrated in vacuo to obtain 0.2817 g of DAW-1-84 as a white solid. The 
product was triturated with CHCl3 to obtain 0.2467 g (57.8%) of pure DAW-1-84 as a white 
powder. 1H NMR (DMSO-d6, 400 MHz) δ 9.32 (s, 2H), 8.77 (t, J=5.5 Hz, 1H), 7.64 (d, J=8.2 
Hz, 2H), 7.45 (d, J=7.8 Hz, 2H), 7.28 (d, J=2.3 Hz, 1H), 7.20 (dd, J=8.3 Hz, 1.8 Hz, 1H), 6.72 
(d, J=8.2 Hz, 1H), 4.45 (d, J=5.5 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 166.77, 149.08, 
148.96, 145.55, 145.44, 128.31, 127.84 (q, J=32.4 Hz), 125.82, 125.63 (q, J=3.8 Hz), 124.91 (q, 
J=270.8 Hz), 119.56, 115.65, 115.41, 42.74; HRMS, DART calcd. for C15H13F3NO3 [M+H]
+ 
312.08476, found: 312.07681. 
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N-(4-(Fluorobenzyl)-3,4-dihydroxybenzamide [DAW-1-86 (CDE-390)] 
To a mixture of 4-fluorobenzylamine (188 µl, 1.65 mmol), 3,4-dihydroxybenzoic acid (211.3 
mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (252.0 mg, 1.647 mmol), N-
methylmorpholine [NMM] (180.0 µl, 1.647 mmol) in methylene chloride (5 ml) in an ice bath, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (315.2 mg, 1.647 
mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred overnight.  The brown reaction mixture was diluted with ≈25 ml of 4:1 of ethyl acetate: 
hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), dried 
over MgSO4, and concentrated in vacuo to obtain 0.1910 g of DAW-1-86 as a white solid. The 
product was triturated with CHCl3 to obtain 0.1524 g (42.5%) of pure DAW-1-86 as a white 
powder. 1H NMR (DMSO-d6, 400 MHz) δ 9.37 (s, 1H), 9.17 (s, 1H), 8.67 (t, J=3.7 Hz, 1H), 7.17 
(m, 6H), 6.71 (dd, J=7.8 Hz, 4.1 Hz, 1H), 4.35 (s, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 
166.62, 161.59 (d, J=240.3 Hz), 148.94, 145.38, 136.77, 129.62 (d, J=8.6 Hz), 126.04, 119.52, 
115.53, 115.51 (d, J=27.6 Hz), 115.32, 42.32; HRMS, DART calcd. for C14H13FNO3 [M+H]
+ 
262.08793, found: 262.08200. 
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Ethyl-2-(2-chlorobenzamide)acetate [DAW-1-88 (CDE-391)] 
To a mixture of glycine ethyl ester hydrochloride (230.0 mg, 1.647 mmol), 2-chlorobenzoic acid 
(214.6 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (252.8 mg, 1.647 mmol), N-
methylmorpholine [NMM] (181.0 µl, 1.647 mmol) in methylene chloride (5 ml) in an ice bath, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (315.5 mg, 1.647 
mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred overnight.  The yellow reaction mixture was diluted with ≈25 ml of 4:1 of ethyl acetate: 
hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), dried 
over MgSO4, and concentrated in vacuo to obtain 0.2929 g (88.34%) of DAW-1-86 as a yellow 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 7.71 (dd, J=7.3 Hz, 1.8 Hz, 1H), 7.36 (m, 3H), 6.81 (s, 
1H), 4.25 (m 4H), 1.31 (t, J=6.9 Hz, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 169.70, 165.95, 
134.23, 131.72, 131.01, 130.48, 130.46, 127.18, 61.82, 42.10, 14.25; HRMS, DART calcd. for 
C11H13ClNO3 [M+H]
+ 242.05839, found: 242.05260. 
 
2- Chloro-N-(2-hydrazinyl-2-oxoethyl)benzamide [DAW-1-90 (CDE-392)] 
To a mixture of DAW-1-88 (101.1 mg, 0.42 mmol) in ethanol (4.2 ml), hydrazine hydrate (~50% 
solution in H2O, 104.5 µl, 1.68 mmol) was added. The white reaction mixture was stirred for 
three days, filtered, and the solid was dried in vacuo to provide 0.0148 g (18.3%) of DAW-1-90 
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as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 9.02 (s, 1H), 8.58 (t, J=5.5 Hz, 1H), 7.41 (m, 
4H), 4.21 (s, 2H), 3.76 (d, J=5.9 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 168.43, 167.08, 
136.82, 131.45, 130.53, 130.18, 129.75, 127.52, 41.56; HRMS, DART calcd. for C9H11ClN3O2 
[M+H]+ 228.05398, found: 228.05170. 
 
 
(S)-Methyl-2-(2-chlorobenzamido)-4-methylpentanoate [DAW-1-91] 
To a mixture of L-leucine methyl ester hydrochloride (300.1 mg, 1.647 mmol), 2-chlorobenzoic 
acid (215.0 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (254.4 mg, 1.647 mmol), N-
methylmorpholine [NMM] (181.0 µl, 1.647 mmol) in methylene chloride (5 ml) in an ice bath, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (315.5 mg, 1.647 
mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred for four days.  The yellow reaction mixture was diluted with ≈25 ml of 4:1 of ethyl 
acetate: hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), 
dried over MgSO4, and concentrated in vacuo to obtain 0.3800 g (97.6%) of DAW-1-91 as a 
yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 7.65 (m, 1H), 7.34 (m, 3H), 6.61 (d, J=7.3Hz, 
1H), 4.84 (m, 1H), 3.76 (s, 3H), 1.72 (m, 3H), 0.99 (d, J=5.5 Hz, 3H), 0.96 (d, J=5.9 Hz, 3H); 
13C NMR (DMSO-d6, 100 MHz) δ 173.24, 166.13, 134.61, 131.56, 130.86, 130.34, 127.14, 
52.45, 51.41, 41.71, 52.01, 22.90, 22.05. 
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(S)-Methyl-2-(2-chlorobenzamido)propanoate [DAW-1-92] 
To a mixture of L-alanine methyl ester hydrochloride (230.3 mg, 1.647 mmol), 2-chlorobenzoic 
acid (215.0 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (253.0 mg, 1.647 mmol), N-
methylmorpholine [NMM] (181.0 µl, 1.647 mmol) in methylene chloride (5 ml) in an ice bath, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (315.8 mg, 1.647 
mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred for four days.  The yellow reaction mixture was diluted with ≈25 ml of 4:1 of ethyl 
acetate: hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), 
dried over MgSO4, and concentrated in vacuo to obtain 0.3026 g (91.26%) of DAW-1-92 as a 
thick yellow oil. 1H NMR (DMSO-d6, 400 MHz) δ 7.67 (dd, J=7.3 Hz, 2.3 Hz, 1H), 7.36 (m, 
3H), 6.83 (d, J=4.6 Hz, 1H), 4.81 (p, J=7.3 Hz, 1H), 3.79 (s, 3H), 1.53 (d, J=6.9 Hz, 3H); 13C 
NMR (DMSO-d6, 100 MHz) δ 173.31, 165.82, 134.51, 131.62, 130.95, 130.41, 130.35, 127.16, 
52.69, 48.79, 18.59. 
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(S)-2- Chloro-N-(1-hydrazinyl-4-methyl-1-oxopentan-2-yl)benzamide [DAW-1-94 (CDE-
401] 
To a mixture of DAW-1-91 (150.5 mg, 0.529 mmol) in ethanol (2.1 ml), hydrazine hydrate 
(~50% solution in H2O, 197.5 µl, 3.174 mmol) was added. The reaction mixture was stirred for 
three days. The brown reaction mixture was diluted with ≈15 ml of dichloromethane and washed 
with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), dried over MgSO4, and 
concentrated in vacuo to obtain 0.0396 g of DAW-1-94 as a light yellow solid. The product was 
triturated with CH3OH to obtain 0.0281 g (18.72%) of pure DAW-1-94 as a pale yellow solid. 
1H NMR (DMSO-d6, 400MHz) δ 11.01 (s, 1H), 8.55 (m, 1H), 7.40 (m, 5H), 5.21 (m, 5H), 4.40 
(m, 1H), 1.84 (m, 2H), 1.58 (m, 1H), 0.86 (m, 6H); 13C NMR (DMSO-d6, 100 MHz) δ 170.25, 
166.16, 145.57, 136.65, 130.68, 129.90, 128.99, 128.19, 49.35, 40.68, 24.47, 23.09, 21.25.  
 
 
(S)-2- Chloro-N-(1-hydrazinyl-2-oxopropan-2-yl)benzamide [DAW-1-96 (CDE-393)] 
To a mixture of DAW-1-92 (127.9 mg, 0.529 mmol) in ethanol (2.0 ml), hydrazine hydrate 
(~50% solution in H2O, 197.5 µl, 3.174 mmol) was added. The milky reaction mixture was 
stirred for three days, filtered, and the solid was dried in vacuo to provide 0.0608 g (47.56%) of 
DAW-1-96 as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 9.06 (s, 1H), 8.51 (d, J=7.8 Hz, 
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1H), 7.39 (m, 4H), 4.37 (p, J=7.4 Hz, 1H), 4.21 (s, 2H), 1.23 (d, J=6.9 Hz, 3H); 13C NMR 
(DMSO-d6, 100 MHz) δ 171.78, 166.37, 136.98, 131.31, 130.51, 130.04, 129.69, 127.44, 47.92, 
18.75; HRMS, DART calcd. for C10H13ClN3O2 [M+H]
+ 242.06962, found: 242.06590. 
 
 
Ethyl-2-(4-chlorobenzylamino)-2-oxoacetate [DAW-11-48 (CDE-444)] 
The solution of 4-chlorobenzylamine (547.5 µl, 4.5 mmol), dry pyridine (1.09 ml, 13.5 mmol) 
and methylene chloride (18 ml) was cooled in an ice bath. Ethyl oxalyl chloride (502.8 µl, 4.5 
mmol) was added and the resulting milky solution was stirred for three days. The clear reaction 
mixture was concentrated to half volume, diluted with ≈50 ml of ethyl acetate and washed with 
0.2N HCl (2x), saturated NaHCO3 (2x), and brine (1x), dried with MgSO4, filtered, and 
concentrated in vacuo to obtain 0.9790 g (90.02%) of DAW-11-48 as a pale yellow solid. 1H 
NMR (CDCl3, 400 MHz) δ 7.40 (s, 1H), 7.28 (m, 2H), 7.21 (m, 2H), 4.47 (d, J=6.4 Hz, 2H), 
4.33 (q, J=6.9 Hz, 2H), 1.37 (t, J=6.9 Hz, 3H); HRMS, DART calcd. for C11H13ClNO3 [M+H]
+ 
242.05839, found: 242.05910. 
 
 
N-(4-chlorobenzyl)-2-hydrazinyl-2-oxoacetamide [DAW-11-50] 
To a mixture of DAW-11-48 (956.1 mg, 3.956 mmol) in ethanol (44.0 ml), hydrazine hydrate 
(~50% solution in H2O, 537.5 µl, 8.643 mmol) was added. The milky reaction mixture was 
stirred for two hours, filtered, and the solid was washed with ethanol, and dried in vacuo to 
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provide 0.7773 g (86.3%) of DAW-11-50 as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 9.99 
(s, 1H), 9.25 (t, J=5.9 Hz, 1H), 7.33 (d, J=8.2 Hz, 2H), 7.23 (d, J=8.2 Hz, 2H), 4.48 (s, 2H), 4.25 
(d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 159.86, 157.94, 137.85, 131.42, 129.19, 
128.19, 41.50. 
 
 
Ethyl-2-(4-chloro-3-(trifluoromethyl)benzylamino)-2-oxoacetate [DAW-11-54] 
A solution of 4-chloro-3-(trifluoromethyl)benzylamine (3.04 ml, 20 mmol), pyridine (4.86 ml, 60 
mmol) and methylene chloride (80 ml) was cooled in an ice bath. Ethyl oxalyl chloride (2.24 ml, 
20 mmol) was added and the resulting milky solution was stirred 48 hours. The reaction mixture 
was concentrated, diluted with ≈75 ml of ethyl acetate and washed with 0.2N HCl (2x) and 
saturated NaHCO3 (2x), and brine, dried with MgSO4, filtered, and concentrated in vacuo to 
obtain 4.98 g (80.4%) of DAW-11-54 as a pale yellow solid. 1H NMR (CDCl3, 400MHz) δ 7.60 
(d, J=1.8 Hz, 1H), 7.45 (m, 3H), 4.53 (d, J=6.4 Hz, 2H), 4.35 (q, J=7.3 Hz, 2H), 1.38 (t, J=7.4 
Hz, 3H). 
 
 
N-(4-Chloro-3-(trifluoromethyl)benzyl)-2-hydrazynil-2-oxoacetamide [DAW-11-56] 
To a mixture of DAW-1-54 (2.5009 g, 8.07 mmol) in ethanol (80.0 ml), hydrazine hydrate 
(~50% solution in H2O, 1.034 ml, 16.15 mmol) was added. The reaction mixture was stirred for 
~2 hours, filtered, triturated with ethanol, and the solid was dried in vacuo to provide 1.843 g 
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(77.3%) of DAW-11-56 as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 10.03 (bs, 1H), 9.36 
(t, J= 5.9 Hz, 1H), 7.72 (s, 1H), 7.64 (d, J=8.3 Hz, 1H), 7.52 (d, J=8.3 Hz, 1H), 4.52 (d, J=3.2 
Hz, 2H), 4.33 (d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 160.03, 157.76, 138.98, 
133.15, 131.57, 129.08, 126.79 (q, J=4.8 Hz), 126.35 (q, J=30.5 Hz), 122.83 (q, J=271.7 Hz), 
41.28.  
 
 
2,21-(Hydrazine-1,2-diyl)bis(N-(4-chloro-3-(trifluoromethyl)benzyl)-2-oxoacetamide) 
[DAW-11-68 (CDE-439)] 
To a mixture of DAW-1-54 (77.4 mg, 0.25 mmol) in ethanol (2.0 ml), DAW-11-56 (73.9 mg, 
0.25 mmol) was added. The reaction mixture was stirred for 6 days while monitoring by thin 
layaer chromatography [TLC] (60% EtOAc : 40% Hexane). Mixture was then refluxed at 60 ºC 
for 24 hours and visualized by TLC using same solvent ratio. After cooling, it was in vacuo and 
solid was triturated with chloroform-D to obtain 0.1235 g of crude DAW-11-68 as a white solid. 
It was purified by a column (eluent - 90% EtOAc : 10% hexane) to afford  0.0527 g (37.7%) of 
DAW-1-68 as a white solid. 1H NMR (CDCl3, 400MHz) δ 9.84 (bs, 2H), 7.92 (bs, 2H), 7.60 (d, 
J=1.8 Hz, 2H), 7.48 (d, J=8.2 Hz, 2H), 7.40 (dd, J=8.2 Hz, 2.3 Hz. 2H), 4.52 (d, J=6.4 Hz, 4H); 
13C NMR (CDCl3, 100 MHz) δ 159.91, 159.57, 154.88, 135.92, 132.12, 131.12, 131.87, 128.78 
(q, J=31.4 Hz), 126.96 (q, J=4.7 Hz), 122.56 (q, J=271.7 Hz), 42.66. 
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N1-(4-Chloro-3-(trifluoromethyl)benzyl)oxalamide [DAW-11-70 (CDE-431)] 
To a mixture of DAW-1-54 (100.1 mg, 0.323 mmol) in ethanol (2.0 ml), 7N ammonia (1 ml) was 
added. The mixture was stirred for two hours, filtered, and the solid was dried in vacuo to provide 
0.0528 g (58.3%) of DAW-11-70 as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 9.35 (t, J=6.4 
Hz, 1H), 8.06 (s, 1H), 7.78 (s, 1H), 7.72 (d, J=1.8 Hz, 1H), 7.64 (d, J=8.2 Hz, 1H), 7.53 (dd, J=8.2 
Hz, 1.4 Hz, 1H), 4.33 (d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 161.89, 160.63, 
138.96, 133.16, 131.58, 129.07, 126.84 (q, J=5.7 Hz), 126.36 (q, J=29.6 Hz), 122.84 (q, J=271.7 
Hz), 41.47; HRMS, DART calcd. for C10H7ClF3N2O2 [M+H]
+ 281.03047, found: 281.02899. 
 
Ethyl 2-(2-(2-(4-chloro-3-(trifluoromethyl)benzylamino)-2-oxoacetyl)hydrazinyl)-2-
oxoacetate [DAW-11-76 / 83] 
A solution of DAW-11-56 (1.0343 g, 3.5 mmol) in dimethyl formamide [DMF] (12.0 ml) and 
pyridine (0.850 ml, 10.5 mmol) was cooled in an ice bath. Ethyl oxalyl chloride (470.0 µl, 4.2 
mmol) was added and the resulting mixture was stirred for five days and visualized by thin layer 
chromatography [TLC] (100% EtOAc). The reaction mixture was concentrated to remove 
pyridine, diluted with 4:1 mixture of ethyl acetate: hexane (≈120 ml) and washed with 0.2N HCl 
(2x) and saturated NaHCO3 (2x), and brine, dried with MgSO4, filtered, and concentrated in 
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vacuo to obtain 0.550 g (39.7%) of DAW-11-76/83 as an off white solid. 1H NMR (DMSO-d6, 
400MHz) δ 10.58 (bs, 1H), 9.35 (bs, 1H), 7.72 (d, J=1.8 Hz, 1H), 7.64 (d, J=8.2 Hz, 1H), 7.53 
(dd, J=8.2 Hz, 1.8 Hz, 1H), 4.34 (d, J=6.4 Hz, 2H), 4.07 (q, J=6.9 Hz, 2H), 1.19 (t, J=6.9 Hz, 
3H). 
 
 
2-(2-(2-(4-Chloro-3-(trifluoromethyl)benzylamino)-2-oxoacetyl)hydrazinyl)-2-oxoacetic 
acid [DAW-11-79 / 80] 
A solution of DAW-11-76 (81.8 mg, 0.207 mmol), 1 M NaOH (1.6 ml), H2O (1.6 ml), and 
ethanol (3.25 ml) was stirred for 1 hour. The reaction mixture was monitored by TLC (100% 
ethyl acetate) and the resulting solution was quenched with 1N HCl (4 ml) and allowed to cool in 
an ice bath for 30 minutes, forming a precipitate. The solid was filtered and dried to provide 
0.478 g (62.8%) of DAW-1-79/80 as a yellow solid. 1H NMR (DMSO-d6, 400MHz) δ 10.76 (s, 
1H), 10.74 (s, 1H), 9.55 (t, J= 6.4 Hz, 1H), 7.74 (s, 1H), 7.66 (d, J=8.2 Hz, 1H), 7.55 (d, J=8.6 
Hz, 1H), 4.36 (d, J=5.9 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 160.95, 159.24, 158.52, 
157.15, 138.68, 133.29, 131.66, 129.22, 126.97 (q, J=4.8 Hz), 126.69 (q, J=31.5 Hz), 122.83 (q, 
J=271.7 Hz), 41.44. 
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N-(4-Chloro-3-(trifluoromethyl)benzyl)-2-(2-(2-hydrazinyl-2-oxoacetyl)hydrazinyl)-2-
oxoacetamide [DAW-11-86 (CDE-441)] 
To a mixture of DAW-11-76/83 (75.2 mg, 0.1895 mmol) in ethanol (1.9 ml), methanol (1.9 ml), 
dichloromethane (0.5 – 1.00 ml), and small amount of water were added to dissolve the 
compound and stirred for two days. Hydrazine hydrate (~50% solution in H2O, 24.5 µl, 0.379 
mmol) was added and the reaction mixture was stirred for another two days, turned into milky 
with fine powder, mixture was dried in vacuo to provide 0.0703 g (97.19%) of DAW-11-86 as a 
white solid. 1H NMR (DMSO-d6, 400MHz) δ 9.10 (bs, 1H), 7.71 (s, 1H), 7.63 (d, J=8.2 Hz, 1H), 
7.53 (d, J=7.3 Hz, 1H), 4.33 (d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 162.33, 
159.42, 156.93, 156.22, 139.33, 133.14, 131.54, 128.99, 126.76 (q, J=4.8 Hz), 126.34 (q, J=30.5 
Hz), 122.86 (q, J=271.7 Hz), 41.35; HRMS, DART calcd. for C12H12ClF3N5O4 [M+H]
+ 
382.05299, found: 382.05020. 
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 2-(2-(2-Amino-2-oxoacetyl)hydrazinyl)-N-(4-chloro-3-(trifluoromethyl)benzyl)-2-
oxoacetamide [DAW-11-87 (CDE-445)] 
To a mixture of DAW-11-76/83 (75.2 mg, 0.1895 mmol) in ethanol (1.9 ml), methanol (1.9 ml), 
dichloromethane (0.5 – 1.00 ml), and small amount of water were added to dissolve the 
compound and stirred for five days. 7N ammonia (1 ml) was added and the reaction mixture was 
stirred for another few days, turned into milky with fine powder, mixture was dried in vacuo to 
provide 0.0694 g (99.87%) of DAW-11-87 as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 
9.67 (bs, 1H), 9.42 (bs, 1H), 9.21 (bs, 1H), 7.95 (bs, 1H), 7.72 (bs, 1H), 7.64 (m, 2H), 7.53 (d, 
J=8.3 Hz, 1H), 4.34 (d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 162.64, 161.60, 
157.63, 157.14, 139.20, 133.17, 131.56, 129.02, 126.82 (q, J=4.7 Hz), 126.35 (q, J=30.5 Hz), 
122.84 (q, J=271.7 Hz), 41.35; HRMS, DART calcd. for C12H11ClF3N4O4 [M+H]
+ 367.04210, 
found: 367.04150. 
 
3,4-Dihydroxy-N-(3,4,5-trifluorobenzyl)benzamide [DAW-11-90 (CDE-453)] 
 To a mixture of 3,4,5-trifluorobenzylamine (200.45 µl, 1.647 mmol), 3,4-dihydroxybenzoic acid 
(211.5 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] (252.2 mg, 1.647 mmol), N-
methylmorpholine [NMM] (181.08 µl, 1.647 mmol) in methylene chloride (5 ml) in an ice bath, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride [EDC•HCl] (315.75 mg, 1.647 
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mmol) was added. The mixture was dissolved by adding dimethylformamide [DMF] (2 ml) and 
stirred overnight.  The brown reaction mixture was reduced in volume in vacuo and the resulting 
solution was diluted with ≈25 ml of 4:1 of ethyl acetate: hexane, and washed with 0.1N HCl 
(2x), saturated NaHCO3 (2x), and brine solution (1x), dried over MgSO4, and concentrated in 
vacuo to obtain 0.3444 g of DAW-11-90 as a white solid. The product was triturated with CHCl3 
to obtain 0.2656 g (65.32%) of pure DAW-11-90 as an off white solid. 1H NMR (DMSO-d6, 400 
MHz) δ 9.45 (bs, 1H), 9.12 (bs, 1H), 8.71 (t, J=5.9 Hz, 1H), 7.26 (d, J=1.8 Hz, 1H), 7.17 (m, 
3H), 6.73 (d, J=8.2 Hz, 1H), 4.34 (d, J=5.9 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 166.30, 
150.04 (ddd, J=245.9 Hz, 9.53 Hz, 2.86 Hz), 148.60, 144.88, 137.95 (t, J=3.8 Hz), 137.43 (dt, 
J=245.9 Hz, 15.2 Hz), 125.14, 119.07, 115.09, 114.88, 111.46 (dd, J=15.2 Hz, 4.7 Hz), 41.58; 
HRMS, DART calcd. for C14H11F3NO3 [M+H]
+ 298.06910, found: 298.06500 
 
N-(4-bromobenzyl)-3-(3,4-dihydroxyphenyl)propanamide [DAW-11-92 (CDE-454)] 
 
To a mixture of 4-bromobenzylamine (306.42 mg, 1.647 mmol), 3-(3,4-
dihydroxyphenyl)propanoic acid (250.0 mg, 1.372 mmol), 1-hydroxybenzotriazole [HOBt•H2O] 
(252.2 mg, 1.647 mmol), N-methylmorpholine [NMM] (181.1 µl, 1.647 mmol) in methylene 
chloride (5 ml) in an ice bath, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
[EDC•HCl] (315.7 mg, 1.647 mmol) was added. The mixture was dissolved by adding 
dimethylformamide [DMF] (2 ml) and stirred overnight.  The brown reaction mixture was 
reduced in volume in vacuo and the resulting solution was diluted with ≈25 ml of 4:1 of ethyl 
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acetate: hexane and washed with 0.1N HCl (2x), saturated NaHCO3 (2x), and brine solution (1x), 
dried over MgSO4, and concentrated in vacuo to obtain DAW-11-92 as a brown oil. The product 
was triturated with CHCl3 to obtain 0.2570 g (53.5%) of pure DAW-1-68 as an off white solid. 
1H NMR (DMSO-d6, 400 MHz) δ 8.67 (bs, 1H), 8.61 (s, 1H), 8.25 (t, J=5.9 Hz, 1H), 7.41 (d, 
J=8.2 Hz, 2H), 7.00 (d, J=8.2 Hz, 2H), 6.55 (m, 2H), 6.39 (dd, J=8.2 Hz, 2.3 Hz, 1H), 4.15 (d, 
J=5.9 Hz, 2H), 2.61 (t, J=8.4 Hz, 2H), 2.31 (t, J=7.8 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 
171.49, 144.96, 143.33, 139.05, 131.92, 130.98, 129.21, 119.53, 118.84, 115.79, 115.36, 41.22, 
37.40, 30.52; HRMS, DART calcd. for C16H17BrNO3 [M+H]
+ 350.03917, found: 350.03479. 
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Chapter III: Small molecule PAI-1 inhibitors using an isosteric replacement of catechol 
 
 
In addition to the modification of the hydrazide-based lead molecule (I-27), I chose to 
simultaneously work on a different project involving isosteres of catechol. Isosteres are 
electronically and/or sterically similar compounds that could improve an inhibitor’s 
pharmacokinetic properties,1and lowering its toxicity while potentially providing the same 
opportunity for hydrogen bonding by using different functional groups.1 The catechol was 
replaced with isosteric indole-based compounds such as oxindole and isatin (Figure 10), as they 
are widely used in pharmaceuticals. It is hoped that they will improve the potency of our 
previous generation polyphenolic inhibitors towards PAI-1 in a plasma-based assay system. 
Therefore, the next step has been to combine the polyphenolic isosteres on different frameworks 
and investigate their structure-activity relationship based on the resulting IC50 values.  
Additionally, pro-drug versions of the hydrazide-based inhibitors using isatin were synthesized 
and were hoped to improve their performance in vivo. 
 
Figure 10: Isosteres and structural modification. (a) Isosteres of catechol. (b) Structural 
modification of oxindole. (c) Structural modification of isatin. 
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III-1: Oxindole-based compounds as inhibitors of PAI-1 
Isosteres of catechol, such as oxindole and isatin, were used to synthesize thiazoles that 
could incorporate the polyphenols on a different central scaffold and allow changes to the 
substitution pattern at the left-hand aromatic moiety. Then the effect of substituting the C3 
position of oxindole via an aldol condensation with various aldehydes was investigated. The 
aldol reaction did not work with hydroxyl-substituted benzaldehyde; therefore, the final 
hydroxyl-substituted product was accessed by demethylating the methoxy-substituted product 
from the previous step with boron tribromide. In addition, the effect that hydrogenation of the 
alkene formed in during the aldol reaction would had on PAI-1 activity was investigated.  
 
Oxindole-based isosteres 
As shown in Scheme 3, oxindole was treated with chloroacetyl chloride and AlCl3 to 
substitute C5 position of oxindole. The resulting product (5-chloroacetyloxindole) was refluxed 
at 80 ºC with variously substituted thiobenzamides to yield the cyclization product2. The 
resulting thiazoles were refluxed at 60 ºC with differently substituted aldehydes in the presence 
of piperidine to yield the aldol products2, which were then demethylated by treatment with boron 
tribromide or hydrogenated by treatment with H2/Pd.  
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Scheme 3: General synthetic method for structural modification for oxindole based compounds 
 
III-2: Effect of changing aromatic ring substituents 
In the thiazole-based oxindoles we changed the substitution pattern on the left-hand 
aromatic ring with methoxy, hydroxy, methyl, CF3, or halogen groups. Then we observed the 
effect on PAI-1 activity according to the change of substituents. We identified that compounds 
with only methoxy or hydroxy groups at the meta or para positions (CDE-227 and CDE-228) 
showed inhibitory activity in standard buffer but both lose activity when plasma is added to the 
assay. CDE-228, which contains a 3,4-dihydroxybenzene group, showed the best inhibitory 
activity with IC50 of 14.8 µM in standard buffer solution. None of the other compounds were 
tested in assays containing 1.5% BSA or plasma due to their lack of activity in standard buffer at 
the concentrations tested. In addition, all of these compounds became insoluble at concentrations 
above 100 µM.  
 
  
N
H
Cl
O
O
R NH2
S
THF/ EtOH
80oC
N
H
O
N
S
R
R, R' = methoxy substituted benzene
polyphenol
benzene
H
O
THF/ EtOH
piperidine
60oC
R'
N
H
O
N
S
R
R'
Cyclizat ion reaction Aldol condenzation
N
H
O
Cl
O
Cl
AlCl3
1,2-dichloroethane
0oC 45oC
Demethylated
product
Hydrogenated
product
Pd/C, H2
1,2-dichloroethane
BBr3, N2
1,2-dichloroethane
Yield: 26-77%
Yield:20-92%
Yield: 10-34%Yield: 89-99%
71 
 
Table 11: Cyclized product with substituted aromatic thiazole amines 
Code R2 R3 R4 R5 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-227a H OCH3 OCH3 H >300 205 NT 
CDE-228a H OH OH H >300 14.8 NT 
CDE-315a H H F H NT >100 NT 
CDE-316a CH3 H Br H NT >100 NT 
CDE-394 H H H H NT >100 NT 
CDE-395b H CF3 H H NT >100 NT 
CDE-396b H H CF3 H NT >100 NT 
CDE-397b H H Br H NT >100 NT 
CDE-398b H Br H H NT >100 NT 
CDE-399 H H Cl H NT >100 NT 
CDE-402 H F H F NT >100 NT 
aCompound synthesized by Hasina Saraha. bCompound synthesized by Naga Guntaka. NT: not 
tested 
 
III-3: Effect of changing substitution on both aromatic rings 
Based on the previous results (Table 11), I chose only methoxy- or hydroxy-substituted 
benzaldehydes to run the aldol condensation because in the presence of other substituents such as 
halides or methyl groups, compounds did not show PAI-1 inhibitory activity. Due to the 
unsuccessful aldol reaction with the hydroxyl-substituted benzaldehyde, I used boron tribromide 
to demethylate the methoxy-substituted compounds. Even though this demethylation provided 
good yield, some of the final products were isolated with impurities (identified with an ‘i’ after 
the compound code).  According to the IC50 values, only the polyphenolic compounds show 
PAI-1 inhibitory activity. The structure-activity relationship indicated that the PAI-1 inhibitory 
activity increased not only with the number of hydroxyl groups, but also is dependent on their 
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position on the aromatic ring. Substituting both the left and right hand sides moieties with a 3,4-
dihydroxybenzene group provided the best IC50 (0.35 µM, Table 12). 
 
Table 12: Aldol condensation and demethylated products with substituted aromatic ring. 
 
Code 
Left Ar Right Ar IC50 (µM) 
R3 R4 R2’ R3’ R4’ R5’ Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-400 H H H H OCH3 H NT >100 NT 
CDE-407 H H H OCH3 OCH3 H NT >100 NT 
CDE-416 H H H OH OH H >100 26.3 >100 
CDE-408 OCH3 OCH3 H OCH3 OCH3 H NT >100 NT 
CDE-411i OH OH H OH OH H >30 0.35 >30 
CDE-417 OH OH H OH H OH >100 25.3 >100 
CDE-418 OH OH OH H H OH >1000 27.6 >1000 
CDE-419i OH OH H H H H NT >100 NT 
NT: not tested 
 
If at least one hydroxyl group was moved from the typical meta and para substitution 
pattern (CDE-416, CDE-417, CDE-418, CDE-419i), potency reduced approximately by 70 -80 
fold, which were given between 25-27 µM (Figure 11).  Comparison of IC50 values indicated 
that substituting both aromatic rings with 3,4-dihydroxybenzene were optimal. However, those 
compounds were not active in assays containing plasma or 1.5% BSA.  
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Figure 11: Comparison of hydroxyl substituents  
 
Moreover, 1H NMR and 13C NMR indicated some of the aldol products (Table 12) were 
a mixture of E/Z isomers in a 3:1 or 4:1 ratio. Therefore, I decided it would be valuable to 
deduce the major component of the mixture. I selected CDE-400 for further analysis and ran an 
NOE experiment with a 5 second mixing time to identify the stereochemistry. According to that 
experiment, I was surprised to find that the final geometry of the CDE-400 sample was 100% E 
isomer (figure 12-a). However, the NOE experiment was run 6 months after synthesis, giving 
the mixture time to equilibrate to a single isomer. 
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Figure 12: (a) Structure of CDE-400 with peak assignments. (b) NOE experiment for CDE-400. 
Proton 2 was irradiated. Signal transmitted to proton 4 and proton 6 through dipolar coupling.  
 
 
III-4: Effect on reduction of alkene group 
There was an attempt to reduce the alkene between the oxindole group and the right hand 
aromatic ring, but the final products were isolated with impurities. However, CDE-409i and 
CDE-410i was sent for biological testing and PAI-1 inhibitory activity was found to be >100 
µM. Due to the difficulty of the purification process, low solubility, and inactivity in the standard 
buffer system, it was not pursued further.  
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Table 13: Hydrogenated products.  
 
Code 
Left Ar Right Ar IC50 (µM) 
R3 R4 R3’ R4’ Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-409i H H OCH3 OCH3 NT >100 NT 
CDE-410i OCH3 OCH3 OCH3 OCH3 NT >100 NT 
NT: not tested, ‘i’: impurities 
 
 
III-5: Isatin based pro-drug formation 
When working on the oxindole-based molecules, it was of interest to determine the effect 
on PAI-1 activity of substituting the acidic proton on the oxindole nitrogen atom. While 
searching the literature, there was a report3 of the use of isatin as an isostere to catechol and 
oxindole (Scheme 4). The article provided an opportunity to pursue a new class of compounds 
by incorporating indole with our previously synthesized hydrazides, discussed in Chapter II. It 
is hoped that this new class of compounds can act as pro-drugs, which means they are 
metabolized in the body to produce the active drug. As stated in Scheme 4, isatin was treated 
with 60% sodium hydride, followed by the respective bromoalkane to obtain the N-alkylated 
product. The resulting alkylated product (or isatin itself, when approporiate) was treated with the 
previously synthesized hydrazide to obtain the desired pro-drug.  
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Scheme 4: General synthetic method for structural modification for isatin based compounds 
 
 
Table 14: IC50 of isatin and N-alkylated product. NT: not tested, NA: not active. 
 
Code R 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
Isatin H NT >3000 NT 
CDE-420  NT >1000 NT 
 
 
Different pro-drug analogues were synthesized by altering the alkyl substituents as well 
as the hydrazides (Table 15). Using the lead compound as the basis for the pro-drug, the 
substitution of the nitrogen atom did not change the IC50 values in standard buffer solution. 
Therefore, those compounds were not tested in assays containing 1.5% BSA or plasma. The pro-
drug of the hydrazide inhibitor that contains our preferred substitution pattern (para-chloro-meta 
trifluoro benzene moiety) with isatin (CDE-449) showed impressive inhibitory activity in 
standard buffer with an IC50 of 11 µM. Due to this result, our collaborators intend to test CDE-
449 in transgenic mice that overexpress PAI-1, these studies will provide the impetus for further 
investigation of prodrugs of the hydrazide class of inhibitors.  
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Table 15: IC50 values of imidated isatin prodrugs 
 
Code R R3 R4 
IC50 (µM) 
Plasma 
PAI-1/uPA 
pH 7.4 
1.5% BSA 
CDE-421  H Cl NT >100 NT 
CDE-425  H Cl NT >300 NT 
CDE-426 H H Cl NT >100 NT 
CDE-449 H CF3 Cl >100 11 >100 
CDE-427 H CF3 F >300 139 >300 
 
 
III-6: Conclusion 
CDE-228 and CDE-411i showed that the 3,4-dihydroxybenzene moiety is very important 
for significant PAI-1 inhibitory activity, while alternate substitution patterns tend to lower 
inhibitory activity. In addition, the oxindole-based compounds have solubility issues and 
therefore they were not tested in assays containing 1.5% BSA or plasma. Therefore, the 
oxindole-based inhibitors need to be further improved to overcome these issues. Considering the 
isatin compounds, substituting the nitrogen atom with an alkyl group did not improve the activity 
against PAI-1. However, the pro-drug version showed improved inhibitory activity when both 
meta and para substituents are present. Also, the activity of CDE-449 confirmed that para-
chloro-meta-trifluorobenzene moiety is beneficial for potential PAI-1 inhibitors, and we are 
evaluating the in vivo results of CDE-449 for further investigations of hydrazide pro-drugs.    
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III-7: Experimental methods and data 
General synthetic methods:  
Unless otherwise noted, all the reactions were performed in 120 ºC oven-dried glassware 
with magnetic stirring. All reagent grade solvents used without purification for extraction, 
chromatography and reactions. Thin layer chromatography (TLC) was performed with 250 mm 
silica gel coated glass plates from Sorbent Technologies, and visualized with 254 nm UV light 
and/or aqueous KMnO4 solution or ninhydrin solution.  Column chromatography was executed 
using silica gel (Sorbent Technologies Premium Rf; 60 Å, 40-75 µM) as the stationary phase. 
1H 
and 13C NMR spectra were obtained with a JEOL ECX-400 spectrometer with a probe 
temperature of 25 ºC using DMSO-d6 (Cambridge Isotope Laboratories, Inc.) or CDCl3 
(Cambridge Isotope Laboratories, Inc.) as solvents. Chemical shifts were measured relative to 
the tetramethylsilane (TMS) peak and were recorded in δ (parts per million, ppm). The internal 
references were DMSO-d6 (δ = 2.50 ppm) for 1H NMR and DMSO-d6 (δ = 39.5 ppm) for 13C 
NMR; CDCl3 (δ = 7.26 ppm) for 1H NMR and CDCl3 (δ = 77.0 ppm) for 13C NMR. Coupling 
constants (J) are recorded in Hertz. Splitting patterns are labeled as follows: bs, broad singlet; s, 
singlet; d, doublet; t, triplet; q, quartet; p, pentet; m, multiplet. High-resolution mass 
spectroscopy data were provided by Prof. Ruth Ann Armitage, Eastern Michigan University, 
Ypsilanti, MI, and were recorded using Direct Analysis in Real Time (DART) from JEOL 
AccuTOF DART instrument, JEOL USA, Inc., Peabody, Massachusetts. 
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Synthetic procedures: 
 
 
 
5-(2-Phenylthiazol-4-yl)indolin-2-one [DAW-1-98/ DAW-11-22 (CDE-394)] 
To a suspension of 5-chloroacetyloxindole [HYS-1-60] (764.1 mg, 3.64 mmol) in a mixture of 
THF/EtOH (9.2 ml/9.2 ml), thiobenzamide (500.7 mg, 3.64 mmol) was added. The mixture was 
refluxed at 80 ºC for 4 hr; the temperature was reduced to 65 ºC due to the evaporation of solvent 
and heated for another 16 hr. After cooling, it was visualized by thin layer chromatography (90% 
EtOAc:10% hexane), and concentrated in vacuo to obtain a solid, which was triturated with ethyl 
acetate to provide 0.6390 g (60.1%) of DAW-1-98 as a brown solid. 1H NMR (DMSO-d6, 400 
MHz) δ 10.48 (s, 1H), 7.98 (m, 3H), 7.85 (m, 2H), 7.49 (m, 3H), 6.86 (d, J=8.2 Hz, 1H), 3.53 (s, 
2H); 13C NMR (DMSO-d6, 100 MHz) δ 176.46, 166.62, 155.48, 143.79, 133.06, 130.29, 129.26, 
127.88, 127.56, 127.25, 126.42, 126.13, 125.71, 122.38, 112.35, 109.22, 35.79; HRMS, DART 
calcd. for C17H13N2OS [M+H]
+ 393.07487, found: 393.06680. 
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5-(2-(4-Chlorophenyl)thiazol-4-yl)indolin-2-one [DAW-1-100 (CDE-399)] 
To a suspension of 5-chloroacetyloxindole [HYS-1-60] (100.2 mg, 0.477 mmol) in a mixture of 
THF/EtOH (2.4 ml/2.4 ml), 4-chlorothiobenzamide (82.1 mg, 0.477 mmol) was added. The 
mixture was refluxed at 65 ºC for 20 hr. After cooling, it was visualized by thin layer 
chromatography (90% EtOAc: 10% hexane), and concentrated in vacuo to obtain a solid, which 
was triturated with ethyl acetate to provide 0.0559 g (35.9%) of DAW-1-100 as a brown solid. 
1H NMR (DMSO-d6, 400 MHz) δ 10.49 (s, 1H), 8.00 (m, 3H), 7.85 (m, 2H), 7.55 (m, 2H), 6.86 
(d, J=8.2 Hz, 1H), 3.53 (s, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 177.00, 165.81, 156.16, 
144.42, 135.32, 132.44, 129.84, 128.37, 127.95, 126.99, 126.29, 122.94, 113.38, 109.76, 36.33; 
HRMS, DART calcd. for C17H12ClN2OS [M+H]
+ 327.03590, found: 327.02701. 
 
 
 5-(2-(3,4-Dimethylphenyl)thiazol-4-yl)indolin-2-one [DAW-1-104/DAW-11-23] 
To a suspension of 5-chloroacetyloxindole [HYS-1-60] (531.2 mg, 2.535 mmol) in a mixture of 
THF/EtOH (12.75 ml/12.75 ml), 4-chlorothiobenzamide (500 mg, 2.535 mmol) was added. The 
mixture was refluxed at 65 ºC for 20 hr. After cooling, it was concentrated in vacuo to obtain a 
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solid, which was triturated with ethyl acetate to provide 0.6897 g (77.2%) of DAW-1-104 as a 
brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.47 (s, 1H), 7.86 (m, 3H), 7.50 (m, 2H), 7.04 
(d, J=7.8 Hz, 1H), 6.86 (d, J=8.7 Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.53 (s, 2H); 13C NMR 
(DMSO-d6, 100 MHz) δ 176.46, 166.72, 155.14, 150.67, 149.03, 143.70, 127.67, 126.37, 126.03, 
125.69, 122.35, 119.36, 111.92, 111.40, 109.19, 109.02, 55.63, 35.8. 
 
(Z)-3-(4-Methoxybenzylidene)-5-(2-phenylthiazol-4-yl)indolin-2-one [DAW-1-108 (CDE-
400)] 
To a mixture of DAW-1-98 (100.1 mg, 0.342 mmol) and 4-methoxybenzaldehyde [p-
anisaldehyde] (42.0 µl, 0.342 mmol) in THF/EtOH (1.72 ml/1.72 ml), piperidine (34.2 µl) was 
added. The mixture was refluxed at 80 ºC for 4 hr. After cooling, the precipitate was filtered and 
washed with ethanol to provide 0.0818 g (58.3%) of DAW-1-108 as a yellow solid. 1H NMR 
(DMSO-d6, 400 MHz) δ 10.67 (bs, 1H), 8.48 (d, J=1.4 Hz, 1H), 7.93 (m, 2H), 7.88 (s, 1H), 7.84 
(dd, J=1.4 Hz, 8.2 Hz, 1H), 7.77 (d, J=8.7 Hz, 2H), 7.63 (s, 1H), 7.48 (m, 3H), 7.14 (d, J=8.7 Hz, 
2H), 6.92 (d, J=8.2 Hz, 1H), 3.87 (s, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 169.02, 167.58, 
166.67, 166.50, 161.32, 160.77, 155.73, 154.94, 142.55, 140.25, 137.48, 136.61, 134.57, 133.10, 
132.99, 131.65, 130.39, 130.31, 129.24, 129.21, 127.46, 127.38, 127.26, 126.97, 126.59, 126.50, 
126.23, 126.00, 125.84, 125.81, 123.80, 121.60, 120.33, 117.22, 114.16, 113.82, 112.43, 112.39, 
110.14, 109.34, 55.49, 55.39; (E and Z rotomers are present). HRMS, DART calcd. for 
C25H19N2O2S [M+H]
+ 411.11671, found: 411.10870. 
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5-(2-(2,4-Difluorophenyl)thiazol-4-yl)indolin-2-one [DAW-1-113 (CDE-402)] 
To a suspension of 5-chloroacetyloxindole [HYS-1-60] (99.9 mg, 0.477 mmol) in a mixture of 
THF/EtOH (2.4 ml/2.4 ml), 4-chlorothiobenzamide (82.9 mg, 0.477 mmol) was added. The 
mixture was refluxed at 80 ºC for two days. It was visualized by thin layer chromatography (80% 
EtOAc: 20% hexane), filtered, and the solid was washed with ethyl acetate to provide 0.0416 g 
(26.6%) of DAW-1-113 as a light pink solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.48 (s, 1H), 
8.37 (dt, J=8.7 Hz, 6.4 Hz, 1H), 8.09 (s, 1H), 7.87 (m, 2H), 7.49 (ddd, J=11.9 Hz, 9.2 Hz, 2.3 
Hz, 1H), 7.27 (dt, J=8.2 Hz, 2.3 Hz, 1H), 6.86 (d, J=8.3 Hz, 1H), 3.53 (s, 2H); 13C NMR 
(DMSO-d6, 100 MHz) δ 176.45, 162.90 (dd, J=249.8 Hz, 12.4 Hz), 159.53 (dd, J=251.7 Hz, 
12.4 Hz), 158.13 (d, J=4.8 Hz), 154.46, 143.90, 130.05 (dd, J=9.5 Hz, 3.8 Hz), 127.30, 126.45, 
125.78, 122.44, 117.59 (dd, J=11.4 Hz, 3.8 Hz), 113.47 (d, J=7.6 Hz), 112.80 (dd, J=21.9 Hz, 
2.9 Hz), 109.23, 104.92 (t, J=26.7 Hz), 35.78; HRMS, DART calcd. for C17H11F2N2OS [M+H]
+ 
329.05601, found: 329.04471. 
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(Z)-3-(3,4-Dimethoxybenzylidene)-5-(2-phenylthiazol-4-yl)indolin-2-one [DAW-11-4/12 
(CDE-407)] 
To a mixture of DAW-1-98 (100.4 mg, 0.342 mmol) and veratraldehyde (57.4 mg, 0.342 mmol) 
in THF/EtOH (1.71 ml/1.71 ml), piperidine (34.2 µl) was added. The mixture was refluxed at 80 
ºC for two days. After cooling, the precipitate was filtered and washed with ethanol to provide 
0.0555 g (36.8%) of DAW-11-4 as a red/yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.67 
(s, 1H), 8.61 (d, J=0.9 Hz, 1H), 7.91 (m, 3H), 7.84 (dd, J=8.2 Hz, 1.4 Hz, 1H), 7.63 (s, 1H), 7.48 
(m, 3H), 7.44 (d, J=1.8 Hz, 1H), 7.37 (dd, J=8.2 Hz, 1.8 Hz, 1H), 7.15 (d, J=8.3 Hz, 1H), 6.92 
(d, J=8.2 Hz, 1H), 3.88 (s, 3H), 3.74 (s, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 169.07, 166.63, 
154.95, 150.57, 148.53, 142.61, 136.92, 132.91, 130.38, 129.24, 129.19, 127.29, 127.20, 126.66, 
126.24, 126.05, 125.63, 123.70, 121.61, 120.54, 112.62, 112.38, 111.69, 110.19, 55.78, 55.36; 
HRMS, DART calcd. for C26H21N2O3S [M+H]
+ 441.12730, found: 441.12711. 
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 3-(3,4-Dimethoxybenzylidene)-5-(2-(3,4-dimethoxyphenyl)thiazol-4-yl)indolin-2-one 
[DAW-11-6/13 (CDE-408)] 
To a mixture of DAW-1-104 (100.0 mg, 0.286 mmol) and veratraldehyde (48.9 mg, 0.286 mmol) 
in THF/EtOH (1.5 ml/1.5 ml), piperidine (29.0 µl) was added. The mixture was refluxed at 80 ºC 
for two days. After cooling, the precipitate was filtered and washed with ethanol to provide 
0.0701 g (49.0%) of DAW-11-6 as a red/yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.67 
(s, 1H), 8.68 (d, J=1.8 Hz, 1H), 8.32 (d, J=1.4 Hz, 1H), 7.92 (s, 1H), 7.87 (m, 3H), 7.55 (m, 2H), 
7.07 (m, 2H), 6.89 (d, J=8.2 Hz, 1H), 3.87 (s, 3H), 3.81 (m, 9H); 13C NMR (DMSO-d6, 100 
MHz) δ 167.64, 166.80, 155.43, 151.25, 150.71, 149.06, 148.00, 140.10, 138.06, 127.59, 127.22, 
126.46, 126.06, 125.87, 123.72, 119.49, 119.45, 117.11, 115.03, 111.95, 111.50, 111.16, 109.34, 
109.28, 55.71, 55.66, 55.58, 55.40; (E and Z rotomers are present). HRMS, DART calcd. for 
C28H25N2O5S [M+H]
+ 501.14630, found: 501.14842. 
 
3-(3,4-Dimethoxybenzyl)-5-(2-phenylthiazol-4-yl)indolin-2-one [DAW-11-8 (CDE-409i)] 
To a stirring mixture of DAW-11-4 (29.5 mg, 0.0681 mmol) in 1,2-dichloroethane (3 ml), a 
small amount of 10% palladium on carbon was added under a hydrogen atmosphere. The 
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mixture was stirred for five days with regular replacement of hydrogen. Completion of the 
reaction was visualized by thin layer chromatography (80% EtOAc: 20% hexane), and the filtrate 
was concentrated in vacuo to obtain 10.3 mg (34.2%) of DAW-11-8 as a dark yellow solid. 1H 
NMR (DMSO-d6, 400 MHz) δ 8.66 (s, 1H), 7.96 (d, J=6.4 Hz, 2H), 7.82 (s, 2H), 7.44 (m, 4H), 
6.96 (m, 4H), 4.11 (m, 9H); HRMS, DART calcd. for C26H23N2O3S [M+H]
+ 443.14293, found: 
443.14001. 
 
3-(3,4-Dimethoxybenzyl)-5-(2-(3,4-dimethoxyphenyl)thiazol-4-yl)indolin-2-one [DAW-11-10 
(CDE-410i)] 
To a stirring mixture of DAW-11-6 (29.4 mg, 0.0681 mmol) in 1,2-dichloroethane (3.5 ml), 
small amount of palladium, 10% on carbon was added under a hydrogen atmosphere. The 
mixture was stirred for five days with regular replacement of hydrogen. Completion of the 
reaction was visualized by thin layer chromatography (80% EtOAc: 20% hexane), and the filtrate 
was concentrated in vacuo to obtain 3.0 mg (10.2%) of DAW-11-10 as a yellow solid. 1H NMR 
(DMSO-d6, 400 MHz) δ 7.84 (m, 2H), 7.56 (m, 5H), 6.95 (m, 3H), 6.70 (m, 1H), 3.87 (m, 15H); 
HRMS, DART calcd. for C28H27N2O5S [M+H]
+ 503.16408, found: 503.15991. 
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3-(2,5-Dimethoxybenzylidene)-5-(2-(3,4-dimethoxyphenyl)thiazol-4-yl)indolin-2-one [DAW-
11-16] 
To a mixture of DAW-1-104 (225.4 mg, 0.639 mmol) and 2,5-dimethoxybenzaldehyde (108.2 
mg, 0.639 mmol) in THF/EtOH (3.2 ml/3.2 ml), piperidine (63.9 µl) was added. The mixture 
was refluxed at 80 ºC for two days. After cooling, the precipitate was filtered and washed with 
ethanol to provide 0.0664 g (20.8%) of DAW-11-16 as a black solid. 1H NMR (DMSO-d6, 400 
MHz) δ 10.69 (s, 1H), 8.42 (s, 1H), 7.84 (dd, J=8.3 Hz, 1.4 Hz, 1H), 7.80 (s, 1H), 7.67 (s, 1H), 
7.45 (dd, J=8.2 Hz, 1.8 Hz, 1H), 7.38 (m, 2H), 7.08 (m, 3H), 6.92 ( d, J=8.2 Hz, 1H), 3.81 (m, 
12H).   
 
(Z)-3-(3,4-Dihydroxybenzylidene)-5-(2-phenylthiazol-4-yl)indolin-2-one [DAW-11-18 
(CDE-416)] 
To a stirring solution of DAW-11-4 (44.0 mg, 0.1 mmol) in 1,2-dichloroethane (1 ml), boron 
tribromide (1.0 ml , 1M in CH2Cl2) was added dropwise under a nitrogen atmosphere. The 
resulting mixture was cooled in an ice bath and allowed to warm at room temperature overnight 
with stirring. The reaction was quenched with few drops of methanol, and the formed precipitate 
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was filtered and washed with ethyl acetate to provide 0.0378 g (91.7%) of DAW-11-18 as a 
yellowish orange solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.64 (s, 1H), 8.31 (s, 1H), 8.20 (d, 
J=1.8 Hz, 1H), 8.02 (m, 3H), 7.85 (m, 1H) 7.75 (m, 2H), 7.49 (m, 3H), 6.85 (d, J=8.2 Hz, 1H), 
6.79 (d, J=8.2 Hz, 1H), 4.02 (bs, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 169.25, 166.54, 155.14, 
148.03, 145.45, 142.33, 139.98, 137.64, 133.10, 132.94, 130.24, 129.33, 129.23, 127.28, 127.24, 
126.36, 126.31, 126.08, 126.05, 125.34, 125.37, 124.48; HRMS, DART calcd. for C24H17N2O3S 
[M+H]+ 413.09599, found: 413.09500. 
 
 
(Z)-3-(3,4-Dihydroxybenzylidene)-5-(2-(3,4-dimethoxyphenyl)thiazol-4-yl)indolin-2-one 
[DAW-11-20 (CDE-411i)] 
To a stirring solution of DAW-11-6 (50.2 mg, 0.1 mmol) in 1,2-dichloroethane (1 ml), boron 
tribromide (1.0 ml , 1M in CH2Cl2) was added dropwise under a nitrogen atmosphere. The 
resulting mixture was cooled down in an ice bath and allowed to warm to room temperature 
overnight with stirring. The reaction was quenched with few drops of water, and the formed 
precipitate was filtered and washed with ethyl acetate to provide 0.0412 g (92.7%) of DAW-11-
20 as a red solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.62 (s, 1H), 8.45 (s, 1H), 8.23 (dd, J=19.2 
Hz, 1.8 Hz, 1H), 7.81 (m, 2H), 7.62 (s, 1H), 7.31 (m, 2H), 6.85 (m, 4H), 4.76 (bs, 4H); HRMS, 
DART calcd. for C24H17N2O5S [M+H]
+ 445.08583, found: 445.08411.  
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3-(3,5-Dihydroxybenzylidene)-5-(2-(3,4-dihydroxyphenyl)thiazol-4-yl)indolin-2-one [DAW-
11-24 (CDE-417)] 
To a mixture of DAW-1-104 (225.1 mg, 0.639 mmol) and 3,5-dimethoxybenzaldehyde (106.4 
mg, 0.639 mmol) in THF/EtOH (3.2 ml/3.2 ml), piperidine (63.9 µl) was added. The mixture 
was refluxed at 80 ºC for two days. After cooling, it was concentrated in vacuo to obtain a brown 
fine solid. The product was triturated with ethanol to provide 0.1400 g (43.8%) of DAW-11-14 
as a brownish/red solid, which was used without further purification. To a stirring solution of 
DAW-11-14 (50.0 mg, 0.1 mmol) in 1,2-dichloroethane (1 ml), boron tribromide (1.0 ml , 1M in 
CH2Cl2) was added dropwise under a nitrogen atmosphere at 0 ºC. The resulting mixture was 
allowed to warm to room temperature overnight with stirring. The reaction was quenched with 
few drops of methanol. A fine solid was formed on addition of ethyl acetate; the mixture was 
concentrated in vacuo and triturated with ethyl acetate to provide 0.0398 g (89.5%) of DAW-11-
24 as a light brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.46 (s, 1H), 7.77 (m, 3H), 7.46-
7.23 (m, 4H), 6.82 (m, 4H); No mass data (entire sample used for biological testing.  
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3-(2,5-Dihydroxybenzylidene)-5-(2-(3,4-dihydroxyphenyl)thiazol-4-yl)indolin-2-one [DAW-
11-26 (CDE-418)] 
To a 0 ºC stirring solution of DAW-11-16 (50.3 mg, 0.1 mmol) in 1,2-dichloroethane (1 ml), 
boron tribromide (1.0 ml, 1M in CH2Cl2) was added dropwise under a nitrogen atmosphere. The 
resulting mixture was allowed to warm to room temperature overnight with stirring. The reaction 
was quenched with few drops of methanol. A solid was formed on addition of ethyl acetate; the 
solid was filtered and triturated with ethyl acetate to provide 0.0440 g (98.9%) of DAW-11-24 as 
a light brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.63 (s, 1H), 8.27 (s, 1H), 7.96 (m, 1H), 
7.81 (dd, J=8.2 Hz, 1.8 Hz, 1H), 7.68 (s, 1H), 7.65 (s, 1H), 7.31 (m, 3H), 7.84 (m, 3H), 5.35 (bs, 
4H); HRMS, DART calcd. for C24H17N2O5S [M+H]+ 445.08583, found: 445.08401. 
 
 
3-Benzylidene-5-(2-(3,4-dimethoxyphenyl)thiazol-4-yl)indolin-2-one [DAW-11-32] 
To a mixture of DAW-11-23 (125.4 mg, 0.3547 mmol) and benzaldehyde (72.0 µl, 0.7094 
mmol) in THF/EtOH (1.77 ml/1.77 ml), piperidine (35.5 µl) was added. The mixture was 
refluxed at 80 ºC for two days. The reaction was visualized by thin layer chromatography (80 % 
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EtOAc : 20 % hexane). After cooling, the brown solid was filtered and triturated with ethanol to 
provide 0.0832 g (53.3%) of DAW-11-32 as a black solid. 1H NMR (DMSO-d6, 400 MHz) δ 
10.72 (s, 1H), 8.34 (s, 1H), 7.85 (dd, J=8.2 Hz, 1.8 Hz, 1H), 7.76 (m, 3H), 7.67 (s, 1H), 7.56 (t, 
J=7.3 Hz, 2H), 7.50 (d, J=7.3 Hz, 1H), 7.45 (dd, J=8.3 Hz, 1.8 Hz, 1H), 7.40 (d, J=1.8 Hz, 1H), 
7.06 (d, J=8.7 Hz, 1H), 6.92 (d, J=8.2 Hz, 1H), 3.84 (s, 3H), 3.81 (s, 3H); 13C NMR (DMSO-d6, 
100 MHz) δ 168.77, 166.78, 154.57, 150.78, 149.01, 142.82, 136.33, 134.42, 129.78, 129.48, 
128.69, 127.98, 127.63, 127.47, 125.88, 121.22, 120.42, 119.39, 111.97, 11.56, 110.3, 108.85, 
55.67. 
 
3-Benzylidene-5-(2-(3,4-dihydroxyphenyl)thiazol-4-yl)indolin-2-one [DAW-11-34 (CDE-
419i)] 
To a 0 ºC stirring solution of DAW-11-32 (44.05 mg, 0.1 mmol) in 1,2-dichloroethane (1 ml), 
boron tribromide (1.0 ml, 1M in CH2Cl2) was added dropwise under a nitrogen atmosphere. The 
resulting mixture was allowed to warm to room temperature overnight with stirring. The reaction 
was quenched with few drops of methanol and few drops of water. The solid was filtered and 
dried under vacuum to provide 0.0457 g (quantitative yield) of DAW-11-34 as a dark yellow 
solid. A mixture of two E/Z isomers are present in the proton and carbon NMR. 1H NMR 
(DMSO-d6, 400 MHz) for isomer A: δ 10.71(s, 1H), 8.38 (d, J=8.2 Hz, 1H), 8.27 (d, J=0.9 Hz, 
1H), 7.85 (s, 1H), 7.80 (dd, J=8.2 Hz, 1.4 Hz, 1H), 7.74 (s, 1H), 7.61 (s, 1H), 7.56 (d, J=7.4 Hz, 
2H), 7.34 (d, J=2.3 Hz, 2H), 7.21 (dd, J=8.3 Hz, 1.8 Hz, 1H), 6.92 (d, J=8.3 Hz, 1H), 6.82 (d, 
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J=8.3 Hz, 1H), 4.04 (s, 2H) and for isomer B: δ 10.73(s, 1H), 8.37 (d, J=7.3 Hz, 1H), 8.32 (d, 
J=0.9 Hz, 1H), 7.92 (s, 1H), 7.87 (dd, J=7.8 Hz, 1.8 Hz, 1H), 7.76 (s, 1H), 7.68 (s, 1H), 7.53 (d, 
J=6.9 Hz, 2H), 7.44 (m, 2H), 7.30 (m, 1H), 6.88 (d, J=8.3 Hz, 1H), 6.81 (d, J=8.2 Hz, 1H), 4.04 
(s, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 168.77, 167.34, 167.28, 167.19, 155.01, 154.36, 
147.95, 147.91, 145.70, 142.70, 140.63, 137.32, 136.35, 134.43, 133.95, 131.99, 130.51, 129.86, 
129.42, 128.77, 128.24, 127.89, 127.81, 127.64, 127.20, 126.65, 125.32, 124.79, 124.73, 121.29, 
120.64, 118.18, 117.97, 117.70, 116.03, 115.97, 113.43, 113.37, 111.01, 110.77, 110.25, 109.49 
; HRMS, DART calcd. for C24H17N2O5S [M+H]+ 413.09599, found:413.09760. 
 
 
1-Pentylindoline-2,3-dione [DAW-11-43 (CDE-420)] 
To a solution of isatin (176.9 mg, 1.2 mmol) in dimethylformamide (3.5 ml), 60% sodium 
hydride (52.9 mg, 1.3 mmol) was added portionwise and stirred for two hours. 1-Bromopentane 
(161.1 µl, 1.3 mmol) was added. The reaction mixture was stirred overnight at room temperature, 
and was visualized by thin layer chromatography (60% EtOAc: 40% hexane). The magenta 
reaction mixture was diluted with ≈24 ml of a 5:1 mixture of ethyl acetate:hexane and washed 
with 0.4N HCl (2x), H2O (1x), dried over MgSO4, and concentrated in vacuo to obtain 0.2405 g 
(92.3%) of DAW-11-43 as a red solid. 1H NMR (CDCl3, 400 MHz) δ 7.57 (m, 2H), 7.10 (t, 
J=7.4 Hz, 1H), 6.88 (d, J=8.2 Hz, 1H), 3.70 (t, J=7.3 Hz, 2H), 1.69 (p, J=7.3 Hz, 2H), 1.35 (m, 
4H), 0,89 (t, J=6.8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ183.63, 158.10, 151.04, 138.27, 
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125.38, 123.55, 117.55, 110.12, 40.21, 28.93, 26.89, 22.24, 13.85; HRMS, DART calcd. for 
C13H16NO2 [M+H]
+ 218.11810, found: 218.11330. 
  
 
 
1-Heptylindoline-2,3-dione [DAW-11-46] 
To a solution of isatin (176.7 mg, 1.2 mmol) in dimethylformamide (3.0 ml), 60% sodium 
hydride (54.2 mg, 1.6 mmol) was added portionwise and stirred for two hours. 1-Bromoheptane 
(205.0 µl, 1.3 mmol) was added. The reaction mixture was stirred overnight at room temperature 
and was visualized by thin layer chromatography (60% EtOAc: 40% hexane). The red reaction 
mixture was diluted with ≈24 ml of a 5:1 mixture of ethyl acetate:hexane and washed with 0.4N 
HCl (2x), H2O (1x), dried over MgSO4, and concentrated in vacuo to obtain 0.2321 g (78.8%) of 
DAW-11-46 as a red oil. 1H NMR (CDCl3, 400 MHz) δ7.57 (m, 2H), 7.10 (t, J=6.9 Hz, 1H), 
6.88 (d, J=8.3 Hz, 1H), 3.70 (t, J=7.3 Hz, 2H), 1.68 (p, J=7.3 Hz, 2H), 1.30 (m, 8H), 0.86 (t, 
J=.6.9 Hz, 3H). 
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N-(4-Chlorobenzyl)-2-oxo-2-(2-(2-oxo-1-pentylindolin-3-ylidene)hydrazynil)acetamide 
[DAW-11-51 (CDE-421)] 
A mixture of DAW-11-43 (108.64 mg, 0.50 mmol) and DAW-11-50 (113.8 mg, 0.50 mmol) in a 
solution of acetic acid (10%), ethanol (45%), and tetrahydrofuran (45%, total of 6.5 ml) was 
stirred for 24 hr at room temperature. The reaction was visualized by thin layer chromatograpghy 
(50% EtOAc : 50% hexane), and concentrated in vacuo to obtain a solid, which was triturated 
with ethanol to provide 0.0936 g (43.9%) of DAW-11-51 as bright orange crystals. 1H NMR 
(CDCl3, 400 MHz) δ 7.80 (d, J=7.3 Hz, 1H), 7.74 (t, J=5.9 Hz, 1H), 7.40 (dt, J=0.9 Hz, 7.8 Hz, 
1H), 7.30 (m, 2H), 7.25 (m, 3H), 7.11 (t, J=7.8 Hz, 1H), 6.87 (d, J=7.8 Hz, 1H), 4.52 (d, J=6.4 
Hz, 2H), 3.74 (t, J=7.3 Hz, 2H), 1.70 (p, J=7.4 Hz, 2H), 1.35 (m, 4H), 0.89 (t, J=6.9 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ161.04, 158.74, 157.27, 143.87, 140.70, 135.24, 133.82, 132.46, 
129.38, 128.96, 123.38, 122.57, 119.23, 109.35, 43.09, 39.91, 28.98, 27.12, 22.27, 13.88; 
HRMS, DART calcd. for C22H24ClN4O3 [M+H]
+ 427.15370, found: 427.15201. 
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N-(4-Chlorobenzyl)-2-oxo-2-(2-(2-oxoindolin-3-ylidene)hydrazynil)acetamide [DAW-11-58 
(CDE-426)] 
A mixture of isatin (73.8 mg, 0.50 mmol) and DAW-11-50 (114.2 mg, 0.50 mmol) in a solution 
of acetic acid (10%), ethanol (45%), and tetrahydrofuran (45%, total of 6.5 ml) was stirred for 24 
hr at room temperature. The reaction was visualized by thin layer chromatograpghy (80% EtOAc 
: 20% hexane), and then concentrated in vacuo to obtain a solid, which was triturated with 
ethanol to provide 0.1084 g (60.8%) of DAW-11-58 as a yellow solid. A mixture of E/Z isomers 
is present in the proton and carbon NMR. 1H NMR (DMSO-d6, 400 MHz) for isomer A: δ 11.58 
(s, 1H), 10.86 (s, 1H), 9.84 (bs, 1H), 7.64 (d, J=7.3 Hz, 1H), 7.41 (m, 5H), 7.09 (t, J=7.8 Hz, 
1H), 6.90 (d, J=7.8 Hz, 1H), 4.36 (d, J=5.9 Hz, 2H), and for isomer B: δ 11.26 (s, 1H), 10.86 (s, 
1H), 9.76 (t, J=6.4 Hz, 1H), 7.55 (d, J=7.3 Hz, 1H), 7.32 (m, 5H), 7.06 (t, J=7.8 Hz, 1H), 6.90 
(d, J=7.8 Hz, 1H), 4.33(d, J=6.4 Hz, 2H)  ; 13C NMR (DMSO-d6, 100 MHz) δ 164.24, 162.52, 
159.32, 159.04, 157.30, 156.78, 144.42, 143.88, 143.12, 140.51, 137.32, 133.70, 132.53, 131.69, 
131.67, 129.43, 128.32, 125.99, 122.77, 122.20, 121.47, 119.54, 115.42, 111.28, 42.04; HRMS, 
DART calcd. for C17H14ClN4O3 [M+H]
+ 357.07545, found: 357.07620. 
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N-(4-Fluoro-3-(trifluoromethyl)benzyl)-2-oxo-2-(2-(2-oxoindolin-3-
ylidene)hydrazynil)acetamide [DAW-11-60 (CDE-427)] 
A mixture of isatin (37.0 mg, 0.25 mmol) and GA-111-93 (69.9 mg, 0.25 mmol) in a solution of 
acetic acid (10%), ethanol (45%), and tetrahydrofuran (45%, total of 3.25 ml) was stirred for 24 
hr at room temperature. The reaction was visualized by thin layer chromatography (80% EtOAc : 
20% hexane), and then concentrated in vacuo to obtain a solid, which was triturated with ethanol 
to provide 0.0508 g (49.8%) of DAW-11-60 as a bright yellow solid. A mixture of E/Z isomers 
are present in the proton and carbon NMR. 1H NMR (DMSO-d6, 400 MHz) for isomer A: δ 
11.58 (s, 1H), 10.86 (s, 1H), 9.87 (bs, 1H), 7.72 (m, 2H), 7.56 (d, J=7.8 Hz, 1H), 7.46 (m, 2H), 
7.09 (t, J=8.2 Hz, 1H), 6.90 (d, J=7.8 Hz, 1H), 4.43 (d, J=6.4 Hz, 2H), and for isomer B: δ 11.26 
(s, 1H), 10.86 (s, 1H), 9.80 (t, J=6.4 Hz, 1H), 7.65 (m, 3H), 7.39 (m, 2H), 7.05 (t, J=8.2 Hz, 1H), 
6.90 (d, J=7.8 Hz, 1H), 4.40(d, J=6.4 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 164.16, 
162.47, 159.38, 159.22, 157.88 (d, J=245.0 Hz), 157.21, 157.16, 144.39, 143.91, 143.87, 143.08, 
140.44, 135.46 (d, J=2.9 Hz), 134.46 (d, J=8.6 Hz), 133.63, 132.46, 126.38 (q, J=3.8 Hz), 
125.99, 122.71, 122.62 (q, J=271.73 Hz), 122.11, 121.41, 119.51, 117.19 (d, J=21.0 Hz), 117.14 
(d, J=20.0 Hz), 115.39, 111.21, 41.59; HRMS, DART calcd. for C18H13F4N4O3 [M+H]
+ 
409.09239, found: 409.09149. 
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N-(4-Chlorobenzyl)-2-(2-(1-heptyl-2-oxoindolin-3-ylidene)hydrazynil)2-oxoacetamide 
[DAW-11-62 (CDE-425)] 
A mixture of DAW-1-46 (122.2 mg, 0.50 mmol) and DAW-11-50 (113.8 mg, 0.50 mmol) in a 
solution of acetic acid (10%), ethanol (45%), and tetrahydrofuran (45%, total of 6.5 ml) was 
stirred for 24 hr at room temperature. The reaction was visualized by thin layer chromatography 
(80% EtOAc : 20% hexane), and then concentrated in vacuo to obtain a solid, which was 
triturated with ethanol to provide 0.0470 g (20.7%) of DAW-11-62 as bright orange crystals.1H 
NMR (CDCl3, 400 MHz) δ 7.80 (d, J=7.3 Hz, 1H), 7.73 (t, J=5.9 Hz, 1H), 7.40 (t, J=7.8 Hz, 
1H), 7.31 (d, J=8.2 Hz, 2H), 7.25 (m, 3H), 7.11 (t, J=7.8 Hz, 1H), 6.87 (d, J=7.8 Hz, 1H), 4.52 
(d, J=5.9 Hz, 2H), 3.73 (t, J=6.9 Hz, 2H), 1.69 (p, J=7.3 Hz, 2H), 1.29 (m, 8H), 0.86 (t, J=6.8 
Hz, 3H) ;13C NMR (CDCl3, 100 MHz) δ 161.04, 158.74, 157.28, 143.88, 140.72, 135.24, 133.84, 
132.46, 129.39, 128.98, 123.38, 122.58, 119.25, 109.36, 43.09, 39.97, 31.62, 28.87, 27.44, 26.88, 
22.54, 14.01; HRMS, DART calcd. for C24H28ClN4O3 [M+H]
+ 455.18498, found: 455.18329. 
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N-(4-chloro-3-(trifluoromethyl)benzyl)-2-oxo-2-(2-(2-oxoindolin-3-
ylidene)hydrazinyl)acetamide [DAW-11-88 (CDE-449)] 
A mixture of isatin (73.6 mg, 0.5 mmol) and DAW-11-56 (147.8 mg, 0.5 mmol) in a solution of 
acetic acid (10%), ethanol (45%), and tetrahydrofuran (45%, total of 6.5 ml) was stirred for three 
days at room temperature. The reaction was visualized by thin layer chromatography (80% 
EtOAc : 20% hexane), and then concentrated in vacuo to obtain a solid, which was triturated 
with ethanol to provide 0.1830 g (86.2%) of DAW-11-60 as a bright yellow solid. A 3:1 mixture 
of E/Z isomers are present in the proton and carbon NMR. 1H NMR (DMSO-d6, 400 MHz) δ 
11.58 (s, 1H, isomer A), 11.26 (s, 1H, isomer B), 10.86 (s, 1H, mixture of A&B), 9.89 (t, J=5.9 
Hz, 1H, isomer A), 9.81 (t, J=6.4 Hz, 1H, isomer B), 7.78 (m, 1H, mixture of A&B), 7.61 (m, 
3H, mixture of A&B), 7.38 (m, 1H, mixture of A&B), 7.07 (m, 1H, mixture of A&B), 6.09 (d, 
J=7.8 Hz, 1H, mixture of A&B), 4.43 (d, J=6.4 Hz, 2H, mixture of A&B); 13C NMR (DMSO-d6, 
100 MHz) δ 164.15, 162.46, 159.42, 159.16, 157.14, 156.61, 144.40, 143.94, 143.08, 140.46, 
138.42, 133.64, 133.33, 132.46, 131.64, 131.61, 129.27, 127.02 (q, J=5.7 Hz), 126.41 (q, J=29.6 
Hz), 125.99, 122.84 (q, J=271.7 Hz), 122.71, 122.12, 121.41, 119.50, 115.37, 11.22, 41.69; 
HRMS, DART calcd. for C18H13ClF3N4O3 [M+H]
+ 425.06282, found: 425.06421. 
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